<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7157695</article-id><article-id pub-id-type="doi">10.3390/vaccines8010098</article-id><article-id pub-id-type="publisher-id">vaccines-08-00098</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The Utility of Human Immune System Mice for High-Containment Viral Hemorrhagic Fever Research</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6719-6931</contrib-id><name><surname>Wozniak</surname><given-names>David M.</given-names></name><xref ref-type="aff" rid="af1-vaccines-08-00098">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5329-4546</contrib-id><name><surname>Lavender</surname><given-names>Kerry J.</given-names></name><xref ref-type="aff" rid="af2-vaccines-08-00098">2</xref></contrib><contrib contrib-type="author"><name><surname>Prescott</surname><given-names>Joseph</given-names></name><xref ref-type="aff" rid="af1-vaccines-08-00098">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5383-0513</contrib-id><name><surname>Spengler</surname><given-names>Jessica R.</given-names></name><xref ref-type="aff" rid="af3-vaccines-08-00098">3</xref><xref rid="c1-vaccines-08-00098" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-vaccines-08-00098"><label>1</label>Center for Biological Threats and Special Pathogens, Robert Koch Institute, 13353 Berlin, Germany; <email>wozniakd@rki.de</email> (D.M.W.); <email>PrescottJ@rki.de</email> (J.P.)</aff><aff id="af2-vaccines-08-00098"><label>2</label>Department of Biochemistry, Microbiology and Immunology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada; <email>kerry.lavender@usask.ca</email></aff><aff id="af3-vaccines-08-00098"><label>3</label>Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA</aff><author-notes><corresp id="c1-vaccines-08-00098"><label>*</label>Correspondence: <email>JSpengler@cdc.gov</email></corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>2</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2020</year></pub-date><volume>8</volume><issue>1</issue><elocation-id>98</elocation-id><history><date date-type="received"><day>22</day><month>12</month><year>2019</year></date><date date-type="accepted"><day>17</day><month>2</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Human immune system (HIS) mice are a subset of humanized mice that are generated by xenoengraftment of human immune cells or tissues and/or their progenitors into immunodeficient mice. Viral hemorrhagic fevers (VHFs) cause severe disease in humans, typically with high case fatality rates. HIS mouse studies have been performed to investigate the pathogenesis and immune responses to VHFs that must be handled in high-containment laboratory facilities. Here, we summarize studies on filoviruses, nairoviruses, phenuiviruses, and hantaviruses, and discuss the knowledge gained from using various HIS mouse models. Furthermore, we discuss the complexities of designing and interpreting studies utilizing HIS mice while highlighting additional questions about VHFs that can still be addressed using HIS mouse models.</p></abstract><kwd-group><kwd>humanized mice</kwd><kwd>HIS mice</kwd><kwd>NSG</kwd><kwd>TKO</kwd><kwd>BLT</kwd><kwd>filovirus</kwd><kwd>Ebola</kwd><kwd>EBOV</kwd><kwd>Marburg</kwd><kwd>Crimean-Congo Hemorrhagic fever</kwd><kwd>Rift Valley Fever</kwd><kwd>hantavirus</kwd><kwd>VHF</kwd><kwd>hemorrhagic fever virus</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-08-00098"><title>1. Introduction</title><p>Viral hemorrhagic fevers (VHFs) are a diverse group of animal and human illnesses that cause severe multisystem dysfunction syndromes, often accompanied by damage to the vascular system and associated signs of hemorrhagic disease. VHFs are a diverse group of RNA viruses including filoviruses, bunyaviruses, arenaviruses, flaviviruses, and rhabdoviruses [<xref rid="B1-vaccines-08-00098" ref-type="bibr">1</xref>]. Research of these highly pathogenic viral families is often limited to high-containment biosafety level 3 (BSL-3) or BSL-4 laboratories due to the severity of the resulting disease and lack of efficacious therapeutics or vaccines. The overall global burden of VHFs has historically been considered low compared to other diseases, such as influenza, human immunodeficiency virus, and malaria. However, it is substantial; annual cases of Lassa fever, for example, are estimated at 100,000&#x02013;300,000 [<xref rid="B2-vaccines-08-00098" ref-type="bibr">2</xref>], and the 2013&#x02013;2016 outbreak of Ebola virus (EBOV; species <italic>Zaire ebolavirus</italic>; family <italic>Filoviridae</italic>) in western Africa [<xref rid="B3-vaccines-08-00098" ref-type="bibr">3</xref>] along with the ongoing outbreak that began in 2018 in the Democratic Republic of Congo [<xref rid="B4-vaccines-08-00098" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-08-00098" ref-type="bibr">5</xref>] highlight the potential for VHFs to cause large-scale international epidemics.</p><p>VHFs are the result of direct virus-mediated effects and, to varying degrees, of both direct and indirect effects of the immune response to infection. Therefore, investigating the immune response during infection is critical for understanding the underlying mechanisms of pathogenesis. However, patient samples are often limited in number and type (restricted to sera or peripheral blood mononuclear cell preparations), particularly for studying early stages of infection, as samples are typically obtained during disease or convalescence. Animal model development aims to characterize species that develop clinical signs and pathology that at least partially recapitulate the clinical course of disease in humans, with the hope that they also mimic the underlying mechanisms of disease. Importantly, animal models can serve as a tool to comprehensively examine immune responses over the course of virus infection. </p><p>Several mouse models have been developed to study VHFs, most of which rely on serially passaging virus to generate a disease-inducing variant or on the use of immunodeficient mouse strains. While there are advantages to studies using mice, the utility of the data generated from these models for understanding human disease is not always clear. To improve the translational quality of mouse models and to facilitate immunological and disease investigations, mice can be engrafted with human cells using a variety of approaches. However, the use of humanized mouse models brings unique disadvantages along with utility. Here, we provide an overview of recent use of human immune system (HIS) mice to study high-containment VHFs, with a focus on filoviruses, nairoviruses, phenuiviruses, and hantaviruses. Herein, we review the work to date involving HIS mice and the knowledge garnered from these models. We then address the complexities of designing and interpreting HIS mouse studies and discuss additional knowledge that can still be gained.</p></sec><sec id="sec2-vaccines-08-00098"><title>2. Background</title><sec id="sec2dot1-vaccines-08-00098"><title>2.1. Humanized Mice</title><p>The term &#x0201c;humanized mice&#x0201d; encompasses a wide range of mouse models that have been manipulated to express human genes, or to support engraftment or transplantation of human cells and/or tissues. &#x0201c;HIS mice&#x0201d; are a subset of humanized mice that are generated by xeno-engrafting human immune cells or tissues and/or their progenitors into immunodeficient mice, and contain viable components of a human immune system. Both the background mouse strain and the humanization procedure contribute to the resulting level of human immune reconstitution and immune system functionality. Overall, HIS models continue to improve as background strains become more immunocompromised and as knowledge of the factors that allow for robust humanization within the xenogeneic murine environment increase. </p></sec><sec id="sec2dot2-vaccines-08-00098"><title>2.2. Generation of HIS Mice</title><p>A variety of background mouse strains are used to generate HIS mice, but all background strains need to be immunodeficient in order to prevent rejection of the human xenograft by the murine immune system. The earliest models took advantage of the severe combined immunodeficiency (SCID) (<italic>Pkrdc</italic><sup>scid</sup>) strain devoid of B and T cells that would otherwise mediate rejection of the human graft [<xref rid="B6-vaccines-08-00098" ref-type="bibr">6</xref>]. Recombination-activating gene knock-out (<italic>Rag</italic><sup>&#x02212;/&#x02212;</sup>) strains are also useful B and T cell-deficient HIS hosts [<xref rid="B7-vaccines-08-00098" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-08-00098" ref-type="bibr">8</xref>]. Back-crossing SCID mice to the NOD strain [<xref rid="B9-vaccines-08-00098" ref-type="bibr">9</xref>] and deleting the common gamma chain (<italic>Il2r</italic>&#x00263;<italic><sub>c</sub></italic><sup>&#x02212;/&#x02212;</sup>) [<xref rid="B10-vaccines-08-00098" ref-type="bibr">10</xref>] on both NOD/SCID [<xref rid="B11-vaccines-08-00098" ref-type="bibr">11</xref>] and <italic>Rag</italic><sup>&#x02212;/&#x02212;</sup> [<xref rid="B12-vaccines-08-00098" ref-type="bibr">12</xref>] backgrounds further improved human graft acceptance, primarily by eliminating natural killer (NK) cell-mediated graft rejection. Additionally, the NOD allele of the inhibitory SIRP<italic>&#x003b1;</italic> receptor recognizes CD47 on human cells, thereby preventing phagocytosis of the xenograft by the murine myeloid compartment in NOD/SCID mice [<xref rid="B13-vaccines-08-00098" ref-type="bibr">13</xref>]. Myeloid-mediated graft rejection in other HIS strains has been surmounted either by knocking in the human <italic>Sirp&#x003b1;</italic> gene [<xref rid="B14-vaccines-08-00098" ref-type="bibr">14</xref>] or by knocking out the murine <italic>Cd47</italic> gene [<xref rid="B15-vaccines-08-00098" ref-type="bibr">15</xref>], resulting in a human xenograft-tolerant phagocytic compartment. With each improvement in overall immunosuppression and tolerance within the murine hosts, human immune engraftment and reconstitution levels have increased both in cell number and repertoire in HIS models.</p><p>While preventing anti-graft immune reactions in the host mouse strain is key to successful reconstitution, additional factors are necessary for optimal development and functionality of the engrafted human immune system. Thus, efforts have been made to remedy these deficiencies by introducing human transgenes into immunodeficient background strains. Mice transgenic for human cytokine genes have improved development of cell lineages reliant on cytokines that are not cross-reactive between mice and humans. For example, mice transgenic for human GM-CSF, IL-3, and SCF support greater development of human myeloid lineages [<xref rid="B16-vaccines-08-00098" ref-type="bibr">16</xref>], whereas mice transgenic for human IL-2 [<xref rid="B17-vaccines-08-00098" ref-type="bibr">17</xref>] and IL-15 [<xref rid="B18-vaccines-08-00098" ref-type="bibr">18</xref>] support better NK cell development and survival. Functionality, as opposed to levels of reconstitution, has also been improved through transgenic expression of human leukocyte antigens (HLA) in graft recipient mouse strains. Mice transgenic for class I and/or class II HLA [<xref rid="B19-vaccines-08-00098" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-08-00098" ref-type="bibr">20</xref>] have T cells educated in the context of human HLA and thus are able to mediate antigen-specific human HLA-restricted T cell responses toward both the HLA-matched human xenograft and the HLA-expressing murine parenchyma. </p><p>The methods used to implant human immune cells and/or tissues into the mouse recipient also impact the level of reconstitution, functionality, and longevity of the human graft. Here we describe three common methods to produce HIS mice. The first method involves injecting peripheral blood leukocytes (PBL) from a human donor directly into an adult mouse [<xref rid="B21-vaccines-08-00098" ref-type="bibr">21</xref>]. The resultant PBL-mice mainly harbor human T cells [<xref rid="B22-vaccines-08-00098" ref-type="bibr">22</xref>] and are particularly useful HIS models for vaccine studies [<xref rid="B23-vaccines-08-00098" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-08-00098" ref-type="bibr">24</xref>]. However, since the immune cells do not develop within the mouse, they are highly xenoreactive, and the mice develop graft versus host disease (GVHD) within months [<xref rid="B25-vaccines-08-00098" ref-type="bibr">25</xref>]. A second method of humanization involves transferring CD34<sup>+</sup> hematopoietic stem cells (HSC) into host animals that have undergone myeloablative conditioning to facilitate implantation and long-term hematopoiesis by the graft. HSCs are sourced from fetal liver, cord blood, bone marrow, or induced in peripheral blood, and can be implanted into either newborn or adult recipient mice to produce humanized mice (hu-mice) [<xref rid="B26-vaccines-08-00098" ref-type="bibr">26</xref>]. Both B and T cells develop within the murine environment, so reconstitution can be sustained for approximately a year with little or no incidence of GVHD. However, immune functionality is not ideal in hu-mice, at least partly due to the lack of HLA-mediated T cell selection in the murine thymus, which since has been improved by using HLA transgenic strains [<xref rid="B19-vaccines-08-00098" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-08-00098" ref-type="bibr">20</xref>]. Lastly, the bone marrow, liver, thymus (BLT) method of humanization also involves transplanting CD34<sup>+</sup> HSCs into preconditioned mice. The HSCs in this model are generated from fetal liver, and small pieces of autologous fetal liver and thymus are additionally implanted under the kidney capsule of the mouse [<xref rid="B27-vaccines-08-00098" ref-type="bibr">27</xref>]. The tissue implant develops into a surrogate human thymus for the maturation and selection of highly functional, HLA-restricted T cells. Unlike other methods, BLT humanization results in sustained and high-level multi-lineage reconstitution, mucosal immunity, antigen-specific B and T cell responses, organized lymphoid tissues, and antibody class-switching [<xref rid="B15-vaccines-08-00098" ref-type="bibr">15</xref>]. Thus, BLT-mice are the most highly reconstituted and functional HIS model produced to date. Nevertheless, the BLT model also has limitations, including an underdeveloped B cell compartment that diminishes over time [<xref rid="B28-vaccines-08-00098" ref-type="bibr">28</xref>] and the development of lethal xenogeneic GVHD [<xref rid="B29-vaccines-08-00098" ref-type="bibr">29</xref>] in some mouse strains. To date, a variety of HIS models has been used to study VHFs, representing each of these humanization approaches (<xref rid="vaccines-08-00098-t001" ref-type="table">Table 1</xref>).</p></sec></sec><sec id="sec3-vaccines-08-00098"><title>3. Use of HIS Mice in VHF Research</title><p>Research involving high-consequence VHFs, including studying immune responses to infection, has long been hampered by the limitations of small animal models. Wild-type laboratory mouse strains, for example, are often resistant to disease with non-adapted viruses, or are overly sensitive to infection, as in the case of Rift Valley fever virus (RVFV) [<xref rid="B32-vaccines-08-00098" ref-type="bibr">32</xref>]. Mice with defective immune systems like SCID and <italic>Rag</italic><sup>&#x02212;/&#x02212;</sup> strains, on the other hand, allow for productive replication of viruses in vivo but with limited pathology. Some disease signs can be recapitulated in mice with defects in the antiviral type I interferon response (<italic>Stat1</italic><sup>&#x02212;/&#x02212;</sup> or <italic>Ifnar</italic><sup>&#x02212;/&#x02212;</sup> strains), supporting in vivo studies of therapeutics [<xref rid="B33-vaccines-08-00098" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-08-00098" ref-type="bibr">34</xref>] and immune modulators [<xref rid="B35-vaccines-08-00098" ref-type="bibr">35</xref>]. However, the underlying disease mechanisms in these models might not truly reflect human disease, and the immune systems of these animals are highly divergent from those of humans, thus greatly limiting the translational quality of the research.</p><p>HIS mouse models are beginning to address a knowledge gap in VHF research, enabling investigations of human immune cell reactions in vivo during productive infection. While research using HIS mice has increased, relatively few VHF studies have been published to date, and these are limited to only a subset of the known high-containment viruses (<xref ref-type="fig" rid="vaccines-08-00098-f001">Figure 1</xref>). However, these studies provide a foundation for advancing VHF work and have provided interesting and novel findings that are reviewed below and summarized in <xref rid="vaccines-08-00098-t002" ref-type="table">Table 2</xref>.</p><sec id="sec3dot1-vaccines-08-00098"><title>3.1. Filoviruses</title><p>Filoviruses like Marburg virus (MARV) and ebolaviruses have been identified as the cause of small human VHF outbreaks since the 1960s and more recently have been the etiologic agents of large-scale outbreaks with high case fatality rates [<xref rid="B3-vaccines-08-00098" ref-type="bibr">3</xref>,<xref rid="B45-vaccines-08-00098" ref-type="bibr">45</xref>]. MARV was the first filovirus discovered in 1967 [<xref rid="B46-vaccines-08-00098" ref-type="bibr">46</xref>,<xref rid="B47-vaccines-08-00098" ref-type="bibr">47</xref>,<xref rid="B48-vaccines-08-00098" ref-type="bibr">48</xref>], following importation to Marburg, Germany, via infected grivets sourced from Uganda for the development of a poliomyelitis vaccine. The first ebolavirus species, <italic>Zaire ebolavirus</italic> (EBOV), was subsequently discovered in 1976 [<xref rid="B49-vaccines-08-00098" ref-type="bibr">49</xref>,<xref rid="B50-vaccines-08-00098" ref-type="bibr">50</xref>,<xref rid="B51-vaccines-08-00098" ref-type="bibr">51</xref>] near the Ebola River in what is now the Democratic of Republic of Congo, and has since posed a major threat to communities in central and western Africa. Currently, six species of ebolaviruses have been described, including EBOV, <italic>Sudan ebolavirus</italic> (SUDV), <italic>Tai Forest ebolavirus</italic> (TAFV), <italic>Bundibugyo ebolavirus</italic> (BDBV), <italic>Reston ebolavirus</italic> (RESTV), and <italic>Bombali ebolavirus</italic> (BOMV). In vitro studies using human monocyte-derived dendritic cells and macrophages have provided strong evidence of the immunotropic nature of filoviruses [<xref rid="B52-vaccines-08-00098" ref-type="bibr">52</xref>,<xref rid="B53-vaccines-08-00098" ref-type="bibr">53</xref>,<xref rid="B54-vaccines-08-00098" ref-type="bibr">54</xref>], which was supported in early non-human primate (NHP) studies [<xref rid="B55-vaccines-08-00098" ref-type="bibr">55</xref>]. Given the central role of immune cell populations in infection and disease, HIS mouse models are particularly interesting for filovirus research by providing a unique opportunity to study human immune cell interactions and responses in vivo.</p><sec id="sec3dot1dot1-vaccines-08-00098"><title>3.1.1. Ebolaviruses</title><p>Early reports of ebolavirus studies in HIS mice were based on work in NOD/SCID <italic>Il2r&#x00263;<sub>c</sub></italic><sup>&#x02212;/&#x02212;</sup> mice engrafted with human PBL (NSG-huPBL) using both mouse-adapted and wild-type EBOV [<xref rid="B36-vaccines-08-00098" ref-type="bibr">36</xref>]. Similar to infection in non-HIS mice, wild-type EBOV infection did not result in lethal disease in NSG-huPBL. Later, studies were performed using more advanced HIS models [<xref rid="B56-vaccines-08-00098" ref-type="bibr">56</xref>,<xref rid="B57-vaccines-08-00098" ref-type="bibr">57</xref>]. The human cell-engrafted NOD.Cg-<italic>Prkdc<sup>scid</sup> Il2rg<sup>tm1Wjl</sup></italic> Tg (HLA-A2.1) 1Enge/Sz mice (hu-NSG-A2) that express human HLA-A2 provided the first platform for a lethal EBOV mouse model without the need of prior virus adaption to the host [<xref rid="B38-vaccines-08-00098" ref-type="bibr">38</xref>]. Lethal disease is observed in hu-NSG-A2 following intraperitoneal [<xref rid="B58-vaccines-08-00098" ref-type="bibr">58</xref>] or intranasal inoculation with the prototypic EBOV Mayinga strain [<xref rid="B37-vaccines-08-00098" ref-type="bibr">37</xref>]. </p><p>EBOV isolated from the more recent West Africa outbreak (Makona strain) can also induce a lethal outcome in hu-NSG-A2 mice, but only to a limited extent [<xref rid="B37-vaccines-08-00098" ref-type="bibr">37</xref>]. When other species of ebolaviruses were evaluated in hu-NSG-A2 mice, SUDV, RESTV, TAFV, and BDBV all caused lower lethality rates than EBOV [<xref rid="B37-vaccines-08-00098" ref-type="bibr">37</xref>], reflecting relative case-fatality rates reported for the respective species in human cases. However, while only non-pathogenic human RESTV infections have been recorded [<xref rid="B59-vaccines-08-00098" ref-type="bibr">59</xref>], RESTV caused a 20% lethality rate in hu-NSG-A2 mice, a rate previously exceeded only in infected NHPs [<xref rid="B60-vaccines-08-00098" ref-type="bibr">60</xref>,<xref rid="B61-vaccines-08-00098" ref-type="bibr">61</xref>]. Lethality in RESTV-infected hu-NSG-A2 mice also differed from the outcome noted in another humanized mouse model, humanized NOD.<italic>Cg-Prkdc<sup>scid</sup> Il2rg<sup>tm1Wjl</sup></italic> Tg (CMV-IL3, CSF2, KITLG) 1Eav/Mloy SzJ (hu-NSG-SGM3) mice. Hu-NSG-SGM3 mice, which are transgenic for human IL-3, CSF-2, and SCF to support improved reconstitution of the human myeloid compartment [<xref rid="B16-vaccines-08-00098" ref-type="bibr">16</xref>], display no disease signs of RESTV infection, even though they provide a disease model for EBOV infection [<xref rid="B42-vaccines-08-00098" ref-type="bibr">42</xref>]. In EBOV-infected hu-NSG-SGM3 mice, murine-origin hepatocytes stained positive for EBOV antigen, and liver damage (histopathology, liver enzyme abnormalities) recapitulated that seen in human disease. In contrast, RESTV infection was mostly restricted to liver macrophages without evidence of hepatic disease. Both EBOV and RESTV replicated to similar titers in hu-NSG-SGM3 mice except in the liver, in which RESTV replicated less efficiently. Although lethality differed in hu-NSG-A2 and hu-NSG-SGM3 mice, notably, both studies indicated an association between viral load in liver and outcome of ebolavirus infection.</p><p>In support of EBOV research in HIS mice, studies in BLT humanized NOD/SCID <italic>Il2r&#x00263;<sub>c</sub></italic><sup>&#x02212;/&#x02212;</sup> mice (NSG-BLT) have demonstrated parallels in immune responses to infection reported in humans and in HIS mice. A massive, non-specific release of host cytokines, or &#x0201c;cytokine storm&#x0201d;, [<xref rid="B62-vaccines-08-00098" ref-type="bibr">62</xref>,<xref rid="B63-vaccines-08-00098" ref-type="bibr">63</xref>] is one aspect of EBOV pathogenesis implicated in severe disease. Cytokine profiles during EBOV infection of NSG-BLT mice [<xref rid="B40-vaccines-08-00098" ref-type="bibr">40</xref>] recapitulated those in fatal human Ebola virus disease (EVD), including high expression of M-CSF, IL-6, IL-8, and TNF&#x003b1;, and the chemokines fractalkin, MIP-1&#x003b2;, and MCP-1 [<xref rid="B62-vaccines-08-00098" ref-type="bibr">62</xref>,<xref rid="B64-vaccines-08-00098" ref-type="bibr">64</xref>,<xref rid="B65-vaccines-08-00098" ref-type="bibr">65</xref>]. Interestingly, the data suggested human donor-specific variations on the outcome of the disease [<xref rid="B40-vaccines-08-00098" ref-type="bibr">40</xref>], which should be considered in conjunction with the possible effects of engraftment efficiency, as was shown in hu-NSG-A2 mice [<xref rid="B38-vaccines-08-00098" ref-type="bibr">38</xref>]. In addition, flow cytometry analysis of human cells in EBOV-infected BLT humanized C57BL/6 <italic>Rag2</italic><sup>&#x02212;/&#x02212;</sup>
<italic>Il2r&#x00263;<sub>c</sub></italic><sup>&#x02212;/&#x02212;</sup>
<italic>Cd47</italic><sup>&#x02212;/&#x02212;</sup> (TKO-BLT) mice [<xref rid="B41-vaccines-08-00098" ref-type="bibr">41</xref>], &#x02248;60% of which succumbed to infection by 22 days post-infection (dpi), suggested that EBOV infection induced myeloid cell dysfunction and skewing of macrophage subsets in vivo at late time points, in line with prior in vitro experiments using human cells [<xref rid="B54-vaccines-08-00098" ref-type="bibr">54</xref>,<xref rid="B55-vaccines-08-00098" ref-type="bibr">55</xref>].</p></sec><sec id="sec3dot1dot2-vaccines-08-00098"><title>3.1.2. MARV</title><p>Studies of MARV infection in HIS mice are much more limited than ebolavirus studies. Only one report, using the TKO-BLT model, investigated MARV infection in HIS mice [<xref rid="B41-vaccines-08-00098" ref-type="bibr">41</xref>]. In humans, MARV disease is comparable in severity to EBOV disease. However, in TKO-BLT mice, MARV infection resulted in limited disease compared to EBOV infection; its cellular tropism was more prolific in murine hepatocytes, with lower levels of infection of Kupffer cells than observed during EBOV infection. In contrast to the skewed and dysfunctional myeloid cell phenotypes observed during EBOV infection, flow cytometric analysis of human cells from MARV-infected animals suggested a more functional and balanced immune response to infection. </p></sec></sec><sec id="sec3dot2-vaccines-08-00098"><title>3.2. Nairoviruses</title><p>Ticks of the genus <italic>Hyalomma</italic> are the main vector Crimean-Congo hemorrhagic fever virus (CCHFV; family <italic>Nairoviridae</italic>, genus <italic>Orthonairovirus</italic>) throughout regions of Mediterranean Europe, Balkans, Middle East, Asia, and Africa. Livestock are prone to infection but remain asymptomatic while still being important for transmitting the virus to humans. In humans, symptoms range from subclinical infection to hemorrhagic syndromes, with fatal outcomes in 5&#x02013;30% of cases [<xref rid="B66-vaccines-08-00098" ref-type="bibr">66</xref>]. Susceptibility to disease from CCHFV in mice has been limited to strains deficient in type I interferon responses [<xref rid="B67-vaccines-08-00098" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-08-00098" ref-type="bibr">68</xref>]. These mice show a very rapid and highly lethal disease progression [<xref rid="B69-vaccines-08-00098" ref-type="bibr">69</xref>,<xref rid="B70-vaccines-08-00098" ref-type="bibr">70</xref>], which is likely largely due to their genetically defective antiviral response rather than a faithful recapitulation of human Crimean-Congo hemorrhagic fever (CCHF)-pathogenesis [<xref rid="B70-vaccines-08-00098" ref-type="bibr">70</xref>]. </p><p>To date, there is only one report on CCHFV in HIS mice. Hu-NSG-SGM3 mice were inoculated intraperitoneally with one of two virus strains: infection with CCHFV-Turkey was uniformly lethal, while CCHFV-Oman-infected mice all survived. Reports of human CCHF case fatality rates suggest that CCHFV is less pathogenic in Turkey than in Oman, but this may be due in part to under-reporting of mild cases in Oman [<xref rid="B71-vaccines-08-00098" ref-type="bibr">71</xref>]. Importantly, while the difference in outcome is notable, these studies were initiated to evaluate outcome in the model and not designed as a direct comparison of strain pathogenicity. Overall, disease progression in hu-NSG-SGM3 mice was slower than in IFN-deficient models, and thus more comparable to human disease. Within inflammatory foci, CCHFV immune reactivity was mostly localized in endothelial cells and immune cells like histiocytes, multinucleated giant macrophages, and Kupffer cells [<xref rid="B43-vaccines-08-00098" ref-type="bibr">43</xref>], but it was unclear whether immune cell targets were of human or murine origin. The main histological finding in lethally CCHFV-Turkey-infected hu-NSG-SGM3 mice was evidence of a neurotropic infection, resulting in meningitis, infection of astrocytes and glial cells, and infiltration of immune cells into the brain [<xref rid="B43-vaccines-08-00098" ref-type="bibr">43</xref>]. Neurological signs in human CCHF have been reported, but are uncommon. The relevance of these findings to human disease remains unclear, as does the mechanism by which the presence of human immune cells may have conferred susceptibility to infection. Investigating CCHFV in HIS mice remains very preliminary. While fatal disease in hu-NSG-SGM3 mice is a promising outcome, additional studies using these and other HIS mice are needed, focusing on the role of the immune response in disease. Such studies will aid in determining the utility of HIS mice in CCHF research.</p></sec><sec id="sec3dot3-vaccines-08-00098"><title>3.3. Phenuivirus</title><p>RVFV (family <italic>Phenuiviridae</italic>, genus <italic>Phlebovirus</italic>) is a mosquito-borne VHF transmitted by six genera of mosquitos, including <italic>Aedes</italic> and <italic>Culex</italic> [<xref rid="B72-vaccines-08-00098" ref-type="bibr">72</xref>], in Sub-Saharan Africa, Egypt, the Arabian Peninsula, and Madagascar. Modeling Rift Valley fever (RVF) disease in mice has been challenging due to the sensitivity of these animals to infection; immunocompetent mice uniformly succumb to disease in 2&#x02013;3 days. This rapid and severe clinical course does not reflect the human phenotype and suggests that underlying mechanisms of human disease are not fully recapitulated. RVFV can strongly inhibit the type I interferon response [<xref rid="B73-vaccines-08-00098" ref-type="bibr">73</xref>], which is a critical factor in disease progression in mice. Artificially attenuating the virus by deleting RVFV&#x02019;s type I interferon-inhibiting NSs gene alleviates the disease in type I interferon-competent mice [<xref rid="B73-vaccines-08-00098" ref-type="bibr">73</xref>]. Studies in HIS mice investigated whether the presence of human immune cells could dampen the clinical course to more accurately model human disease. However, intramuscularly infected hu-NSG-SGM3 mice succumbed to disease at similarly fast rates [<xref rid="B44-vaccines-08-00098" ref-type="bibr">44</xref>]. Human cytokine expression in the hu-NSG-SGM3 model in part mirrored cytokines seen in fatal patient outcomes, but increased expression of murine cytokines was also observed during infection. This highlights the importance of considering the remaining immune function of the murine background of HIS mice when evaluating the role of immune responses in disease progression.</p></sec><sec id="sec3dot4-vaccines-08-00098"><title>3.4. Hantaviruses</title><p>Hantaviruses are harbored by rodents, shrews, and bats, but only rodent-borne hantaviruses have been reported to cause hemorrhagic syndromes in humans [<xref rid="B74-vaccines-08-00098" ref-type="bibr">74</xref>]. Hantavirus research using HIS mice is limited. The only study to date compared human HSC-engrafted NSG mice (hu-NSG) with hu-NSG-A2 mice in regard to possible cytotoxic T lymphocyte (CTL)-induced immunopathologies during infection with Hantaan virus (HTNV; family <italic>Hantaviridae</italic>, genus <italic>Orthohantavirus</italic>) [<xref rid="B45-vaccines-08-00098" ref-type="bibr">45</xref>]. HTNV-induced disease progression was accelerated in the HLA-A2-expressing hu-NSG-A2 mice compared to hu-NGS mice that did not express transgenic human MHC I, despite similar viral replication in both models. Endothelial cells are considered the primary target cells of hantaviruses [<xref rid="B75-vaccines-08-00098" ref-type="bibr">75</xref>]. Expression of human HLA-A2 on murine endothelia in the hu-HLA-A2 mouse would allow them to be targeted by CTLs, possibly contributing to the accelerated pathology observed in this model. HTNV infection caused a reduction in human platelet counts in hu-NSG-A2 mice while murine platelets remained unaffected. While a clear explanation for this phenomenon is missing, elimination of virally infected human megakaryocytes or platelets in HLA-A2-expressing mice or differing human and murine &#x003b2;3 integrin interactions with hantaviruses on activated platelets could be responsible [<xref rid="B45-vaccines-08-00098" ref-type="bibr">45</xref>].</p></sec></sec><sec id="sec4-vaccines-08-00098"><title>4. What We Have Learned about Using HIS Mice for VHF Studies</title><p>Overall, we have learned that HIS mice do not completely model human disease, even though VHF infection may result in clinical disease and pathology. Nonetheless, they serve as useful tools for studying specific events in virus infection. VHF studies to date have demonstrated that HIS models only occasionally recapitulate a subset of features of human disease. This is not unexpected, as the human immune features of each specific HIS model influence the disease process. For example, CTL-mediated pathogenesis has been observed in the hu-NSG-A2 model of EBOV [<xref rid="B37-vaccines-08-00098" ref-type="bibr">37</xref>] resulting in liver pathology. This is due to the expression of HLA-A2-restricted epitopes that can be presented by infected murine cells and targeted by human CTLs. However, CD4<sup>+</sup> T cell responses and several other compartments of the immune system are deficient, limiting modeling of all immune aspects that contribute to this and other features of disease. Similarly, hepatic pathology has been observed in the hu-NSG-SGM3 model of EBOV [<xref rid="B39-vaccines-08-00098" ref-type="bibr">39</xref>], but likely occurred through an alternative mechanism with myeloid cell involvement. Therefore, although hepatocytes are infected in both models during EBOV infection, independent mechanisms contribute to liver disease in each one.</p><p>HIS mouse studies to date have shown value in investigating individual immune pathways, but have not provided a definitive answer regarding the most important events in human disease, nor a complete system to examine interrelated events. These events include dendritic cell and macrophage infection; immune target cell dysregulation; antigen presentation to CD4<sup>+</sup> T cells; involvement of B cells and antibody responses; infection of parenchymal cells; and killing of infected cells by CTL or NK cells. The interactions that can be investigated vary dramatically depending on the mouse model. For example, adding thymus xenografts to the HIS model allows T cells to be educated on the human thymus and to recognize antigens presented by human antigen presenting cells. On the other hand, CD8<sup>+</sup> T cells only incidentally interact with murine MHC I but provide a more complete picture of the early events in which dendritic cells, macrophages, and monocytes are infected or take up antigen and present antigen to T cells and B cells, thereby activating these cells. While not an accurate model of VHF disease course from beginning to end, HIS mice provide a more faithful human immune system to examine specific features in a hypothesis-driven manner. For example, by comparing various viruses using the BLT system we have found that differences in dendritic cell and T cell responses exist and can be characterized even between closely related viruses [<xref rid="B41-vaccines-08-00098" ref-type="bibr">41</xref>]. </p></sec><sec id="sec5-vaccines-08-00098"><title>5. Limitations of HIS mice</title><p>Introducing human cells into mice using any of the approaches described to date does not result in the same proportions of immune cells as seen in humans. Transgenic expression of human cytokines in HIS mice [<xref rid="B16-vaccines-08-00098" ref-type="bibr">16</xref>], as well as the use of BLT xenografts, has drastically improved these models [<xref rid="B15-vaccines-08-00098" ref-type="bibr">15</xref>]. Furthermore, regardless of the model, generation of HIS mice results in experimental subjects that often differ in their immune system composition, introducing complex variability into experiments. Donor material can also vary from batch to batch and from institution to institution. The presence of these confounding variables is challenging for study design and data interpretation, requiring more test subjects. Despite these challenges, the possibility of studying immune systems of differing human genetic backgrounds is also a great advantage of humanized mouse models. Another powerful feature of HIS mice is that multiple genetically identical animals can be produced from the human-sourced tissue, providing a means for experimentation using multiple &#x0201c;clones&#x0201d; of a single human immune system. </p><p>HIS mouse model limitations vary, specifically when considering which aspects of the immune response can be investigated in disease. For example, although human immune cells can react natively to viruses surveyed from their surroundings or introduced through infection of the immune cells, human CD8<sup>+</sup> T cell interaction with murine parenchymal cells is severely limited in most HIS models. Without the expression of human MHC I on mouse cells, an important part of the antiviral immune response by CD8<sup>+</sup> T cells is absent. Non-hematopoietic cells in these mouse models are often antigen-positive for virus. Especially common is the infection of endothelial cells [<xref rid="B41-vaccines-08-00098" ref-type="bibr">41</xref>,<xref rid="B42-vaccines-08-00098" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-08-00098" ref-type="bibr">43</xref>] as well as infection of hepatocytes and Kupffer cells [<xref rid="B41-vaccines-08-00098" ref-type="bibr">41</xref>,<xref rid="B76-vaccines-08-00098" ref-type="bibr">76</xref>,<xref rid="B77-vaccines-08-00098" ref-type="bibr">77</xref>]. CD8<sup>+</sup> T cell responses are thought to be important in the development of disease caused by VHFs [<xref rid="B78-vaccines-08-00098" ref-type="bibr">78</xref>,<xref rid="B79-vaccines-08-00098" ref-type="bibr">79</xref>,<xref rid="B80-vaccines-08-00098" ref-type="bibr">80</xref>]. Transgenic expression of human MHC I molecules in HIS mice [<xref rid="B38-vaccines-08-00098" ref-type="bibr">38</xref>,<xref rid="B45-vaccines-08-00098" ref-type="bibr">45</xref>] was attempted to address this problem, but this approach restricts the CD8 T cell responses to only HLA-A2-compatible viral epitopes and T cell receptors, even though many other immune-dominant epitopes exist for other MHC I alleles (e.g., A3 and B7) [<xref rid="B81-vaccines-08-00098" ref-type="bibr">81</xref>].</p><p>Other limitations are more universal to current HIS mouse models, including the inability to research the influence of any antibody isotypes besides IgM on viral infection; this is due to severely limited class switching from IgM to other isotypes in most humanized mouse models [<xref rid="B82-vaccines-08-00098" ref-type="bibr">82</xref>]. The effect of neutralizing antibodies on disease outcome is significant in VHFs like EVD [<xref rid="B83-vaccines-08-00098" ref-type="bibr">83</xref>,<xref rid="B84-vaccines-08-00098" ref-type="bibr">84</xref>]. However, non-neutralizing antibodies can also fulfill important roles in opsonization, activation of complement [<xref rid="B81-vaccines-08-00098" ref-type="bibr">81</xref>] and antibody-dependent cellular cytotoxicity (ADCC) [<xref rid="B85-vaccines-08-00098" ref-type="bibr">85</xref>] during disease. While neither phagocytosis nor ADCC are effectively mediated by antibodies of the IgM isotype, IgM does effectively activate complement. Complement activation is impaired in NSG mice due to a C5 deficiency [<xref rid="B86-vaccines-08-00098" ref-type="bibr">86</xref>] but HIS models based on the C57BL/6 [<xref rid="B15-vaccines-08-00098" ref-type="bibr">15</xref>] or other complement-competent background strains could be used to study this effector mechanism. In vivo mouse studies of complement-dependent tumor depletion by the humanized Rituximab antibody [<xref rid="B87-vaccines-08-00098" ref-type="bibr">87</xref>] suggest that human antibodies would be able to activate mouse complement in HIS models.</p><p>Other factors that create challenges in HIS mouse studies are the dynamic relationships between human and mouse cells and their respective immune responses. In HIS mice, much of the murine immune system is absent or non-functional due to genetic modification or irradiation, limiting the influence of the murine immune response. However, residual immune cells and other cells that produce cytokines and innate immune mediators, such as type I interferons are present in HIS mice. This response likely influences not only the outcome of infection, but also the responses of the human immune cells. While murine responses to VHF infection in HIS mice have been described [<xref rid="B44-vaccines-08-00098" ref-type="bibr">44</xref>], studies to date have not specifically addressed how the background murine response might influence the activities of the human immune system in these mice.</p><p>In HIS mice, there is a disconnect between the cytokine response of the human immune system, and both the remaining mouse myeloid system and the non-hematopoietic mouse cells. While immune cells are often considered the main producers of important cytokines, other cells can also strongly impact the cytokine milieu [<xref rid="B88-vaccines-08-00098" ref-type="bibr">88</xref>]. Thus, non-hematopoietic murine endothelia and hepatocytes could contribute significantly to cytokine production, along with other murine myeloid cells that many VHFs preferentially infect. Limited cross-reactivity of human and mouse cytokines [<xref rid="B89-vaccines-08-00098" ref-type="bibr">89</xref>] prevents a full assessment of causes and effects in these models, as does omitting or neglecting assessment of mouse cytokines during these studies. Unobserved parallel murine cytokine messaging from endothelial or other murine cells harboring virus could occur in HIS mouse disease models [<xref rid="B41-vaccines-08-00098" ref-type="bibr">41</xref>,<xref rid="B42-vaccines-08-00098" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-08-00098" ref-type="bibr">43</xref>], but is not commonly investigated. Even less is known about the extent of human immune cell interactions with murine tissue ligands. Tissue ligands are another important factor of communication to immune cells, yet by not studying cross-reactive effects between mice and humans, the immune cells are essentially kept in undefined stimulatory milieus. Finally, VHFs also target non-immune cells during infection [<xref rid="B41-vaccines-08-00098" ref-type="bibr">41</xref>,<xref rid="B42-vaccines-08-00098" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-08-00098" ref-type="bibr">43</xref>], which further complicates studies in HIS mice due to the limited interaction of human immune cells with murine soma. In the absence of key murine immune cells, viral infection of murine cells cannot be ordinarily antagonized, which may additionally alter recapitulation of immunological events found in natural infection.</p></sec><sec sec-type="conclusions" id="sec6-vaccines-08-00098"><title>6. Conclusions</title><p>VHF research in humanized mouse models remains in its infancy, as we continue to learn about the limitations and utility of these models. Although generating HIS mouse models and interpreting data from such studies may be more complex than using other mouse models, HIS mice remain a valuable tool to model HIS responses and interactions in vivo; in particular for analyzing organ-specific immune reactions and infection patterns. For example, while using rodent-adapted virus in mice may generate uniform lethality, these models may not be as informative for human disease when examining the interaction between the virus and various components of the immune system. In addition, aspects of human disease progression may be reflected better in HIS mice. For example, CCHFV studies are restricted to type I interferon-deficient mice, in which infection progresses too rapidly for sufficient investigation of the immune responses [<xref rid="B67-vaccines-08-00098" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-08-00098" ref-type="bibr">68</xref>,<xref rid="B69-vaccines-08-00098" ref-type="bibr">69</xref>,<xref rid="B70-vaccines-08-00098" ref-type="bibr">70</xref>]. In HIS mice, CCHF progression was delayed compared to <italic>Ifnar<sup>&#x02212;/&#x02212;</sup></italic> models, offering novel opportunities for immunological investigations.</p><p>Many questions remain about VHF diseases that may be addressed in HIS mice. The factors that differentiate why some people develop subclinical infection while others develop severe or fatal disease are unknown, for example. Using different donors for humanized mouse generation could be helpful in revealing whether underlying donor differences in the immune system could be responsible for such strongly divergent outcomes of infection. Additionally, some VHFs have yet to be investigated in HIS mice, including, notably, arenaviruses. The family <italic>Arenaviridae</italic> includes many hemorrhagic fever-causing species [<xref rid="B90-vaccines-08-00098" ref-type="bibr">90</xref>] that are predominantly spread by small rodents, but few aspects of human immune responses to these viruses are known. For example, most immunological knowledge of humans with Lassa fever, the most characterized arenaviral disease, is based on a few case studies of single patients [<xref rid="B91-vaccines-08-00098" ref-type="bibr">91</xref>], single cases evacuated to first-world countries [<xref rid="B92-vaccines-08-00098" ref-type="bibr">92</xref>,<xref rid="B93-vaccines-08-00098" ref-type="bibr">93</xref>], and serological studies [<xref rid="B94-vaccines-08-00098" ref-type="bibr">94</xref>], leaving large sets of immunological analyses still unexplored. NHPs [<xref rid="B95-vaccines-08-00098" ref-type="bibr">95</xref>,<xref rid="B96-vaccines-08-00098" ref-type="bibr">96</xref>,<xref rid="B97-vaccines-08-00098" ref-type="bibr">97</xref>,<xref rid="B98-vaccines-08-00098" ref-type="bibr">98</xref>] and small animal models like guinea pigs [<xref rid="B99-vaccines-08-00098" ref-type="bibr">99</xref>,<xref rid="B100-vaccines-08-00098" ref-type="bibr">100</xref>,<xref rid="B101-vaccines-08-00098" ref-type="bibr">101</xref>] and type I interferon-deficient mouse strains (<italic>Ifnar<sup>&#x02212;/&#x02212;</sup></italic> and <italic>Stat1</italic><sup>&#x02212;/&#x02212;</sup>) [<xref rid="B33-vaccines-08-00098" ref-type="bibr">33</xref>,<xref rid="B79-vaccines-08-00098" ref-type="bibr">79</xref>,<xref rid="B102-vaccines-08-00098" ref-type="bibr">102</xref>,<xref rid="B103-vaccines-08-00098" ref-type="bibr">103</xref>] are commonly used to study these diseases. Even though human immune cells are considered an early target of arenaviruses, no studies in humanized mice have yet been published [<xref rid="B104-vaccines-08-00098" ref-type="bibr">104</xref>,<xref rid="B105-vaccines-08-00098" ref-type="bibr">105</xref>].</p><p>New HIS mouse models are being developed that may advance our knowledge of VHFs. Numerous methods are being introduced to express human cytokines in HIS models such as transgenic expression, injection of recombinant proteins or plasmid DNA, or use of adenovirus- associated viruses to express proteins of interest. Additionally, mouse backgrounds expressing additional HLA class I alleles, including HLA-A2, A11, A24, B7, B27, and Cw3, and class II alleles like HLA-DR1, DR2, DR3, DR4, and DQ8 [<xref rid="B106-vaccines-08-00098" ref-type="bibr">106</xref>], either alone or in combination, are currently in development. Efforts are also underway to find ways to enhance the function of the universally underdeveloped and short-lived B cell compartment, including transgenic expression of human MHC II [<xref rid="B107-vaccines-08-00098" ref-type="bibr">107</xref>], transgenic expression of human IL-6 [<xref rid="B108-vaccines-08-00098" ref-type="bibr">108</xref>], and knockout of the <italic>Cmah</italic> gene in the murine background [<xref rid="B109-vaccines-08-00098" ref-type="bibr">109</xref>]. Knocking out murine MHC has also been shown to reduce incidence of GVHD in susceptible strains [<xref rid="B110-vaccines-08-00098" ref-type="bibr">110</xref>]. </p><p>Current HIS models all have potential benefits and drawbacks that need to be considered during experimental design. Thus, choosing the most appropriate HIS model for any experiment requires careful reflection of whether the hypothesis can be tested based on the specific functional components of the model and the interplay between immune components of both murine and human origin. Ultimately, new HIS models should aim to more fully recapitulate all the interconnected facets of immunity. We envision a time when HIS models are combined to take advantage of key modifications to enhance all aspects of immunity, like, for example, BLT humanization of an immunodeficient strain that exhibits GVHD resistance and expresses full graft-matched HLA class I and II haplotypes and a suite of essential human cytokines.</p><p>The initially intended application of HIS mice to VHF research was two-fold: to establish a small animal model that more faithfully recapitulated human disease, and to advance investigations into the role of the immune system in infection and disease. We have learned that engraftment of human immune cells and tissues is not sufficient to completely mirror human disease and that the lack of a direct interaction between human immune cells and the murine parenchyma may be the primary limitation in modeling pathology. Still, much has been learned and remains to be investigated regarding the involvement of the immune response in VHF disease, components of which can be studied using HIS mice. Currently, no vaccine evaluations in HIS mice for the viruses discussed here have been reported. However, given the infancy of the field, continuing to understand the models, particularly for VHFs, is necessary for designing and interpreting any putative vaccine work in the future. Studies to date have highlighted the challenges and complexities of HIS mouse studies. Nonetheless, the use of HIS mice in VHF research has been informative. Current and newly developed HIS models will continue to enable the study of complex immune interactions that occur in vivo upon infection and provide valuable insight into the human immune response to VHFs.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank Tatyana Klimova for assistance in editing the manuscript.</p></ack><notes><title>Funding</title><p>This work was supported in part from CDC emerging infectious disease research core funds.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><notes><title>Disclaimer</title><p>The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-08-00098"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grard</surname><given-names>G.</given-names></name><name><surname>Fair</surname><given-names>J.N.</given-names></name><name><surname>Lee</surname><given-names>D.</given-names></name><name><surname>Slikas</surname><given-names>E.</given-names></name><name><surname>Steffen</surname><given-names>I.</given-names></name><name><surname>Muyembe</surname><given-names>J.-J.</given-names></name><name><surname>Sittler</surname><given-names>T.</given-names></name><name><surname>Veeraraghavan</surname><given-names>N.</given-names></name><name><surname>Ruby</surname><given-names>J.G.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><etal/></person-group><article-title>A Novel Rhabdovirus Associated with Acute Hemorrhagic Fever in Central Africa</article-title><source>PLoS Pathog.</source><year>2012</year><volume>8</volume><elocation-id>e1002924</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1002924</pub-id><pub-id pub-id-type="pmid">23028323</pub-id></element-citation></ref><ref id="B2-vaccines-08-00098"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCormick</surname><given-names>J.B.</given-names></name><name><surname>Webb</surname><given-names>P.A.</given-names></name><name><surname>Krebs</surname><given-names>J.W.</given-names></name><name><surname>Johnson</surname><given-names>K.M.</given-names></name><name><surname>Smith</surname><given-names>E.S.</given-names></name></person-group><article-title>A prospective study of the epidemiology and ecology of Lassa fever</article-title><source>J. Infect. Dis.</source><year>1987</year><volume>155</volume><fpage>437</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1093/infdis/155.3.437</pub-id><?supplied-pmid 3805771?><pub-id pub-id-type="pmid">3805771</pub-id></element-citation></ref><ref id="B3-vaccines-08-00098"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baize</surname><given-names>S.</given-names></name><name><surname>Pannetier</surname><given-names>D.</given-names></name><name><surname>Oestereich</surname><given-names>L.</given-names></name><name><surname>Rieger</surname><given-names>T.</given-names></name><name><surname>Koivogui</surname><given-names>L.</given-names></name><name><surname>Magassouba</surname><given-names>N.</given-names></name><name><surname>Soropogui</surname><given-names>B.</given-names></name><name><surname>Sow</surname><given-names>M.S.</given-names></name><name><surname>Ke&#x000ef;ta</surname><given-names>S.</given-names></name><name><surname>De Clerck</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Emergence of Zaire Ebola Virus Disease in Guinea</article-title><source>N. Engl. J. Med.</source><year>2014</year><volume>371</volume><fpage>1418</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1404505</pub-id><pub-id pub-id-type="pmid">24738640</pub-id></element-citation></ref><ref id="B4-vaccines-08-00098"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barry</surname><given-names>A.</given-names></name><name><surname>Ahuka-Mundeke</surname><given-names>S.</given-names></name><name><surname>Ali Ahmed</surname><given-names>Y.</given-names></name><name><surname>Allarangar</surname><given-names>Y.</given-names></name><name><surname>Anoko</surname><given-names>J.</given-names></name><name><surname>Nicholas Archer</surname><given-names>B.</given-names></name><name><surname>Aruna Abedi</surname><given-names>A.</given-names></name><name><surname>Bagaria</surname><given-names>J.</given-names></name><name><surname>Roseline Darnycka Belizaire</surname><given-names>M.</given-names></name><name><surname>Bhatia</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Outbreak of Ebola virus disease in the Democratic Republic of the Congo, April&#x02013;May, 2018: An epidemiological study</article-title><source>Lancet</source><year>2018</year><volume>392</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)31387-4</pub-id><pub-id pub-id-type="pmid">30047375</pub-id></element-citation></ref><ref id="B5-vaccines-08-00098"><label>5.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>WHO</collab></person-group><source>Ebola Virus Disease&#x02013;Democratic Republic of the Congo</source><publisher-name>WHO</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2020</year></element-citation></ref><ref id="B6-vaccines-08-00098"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greiner</surname><given-names>D.L.</given-names></name><name><surname>Hesselton</surname><given-names>R.A.</given-names></name><name><surname>Shultz</surname><given-names>L.D.</given-names></name></person-group><article-title>SCID Mouse Models of Human Stem Cell Engraftment</article-title><source>Stem Cells</source><year>1998</year><volume>16</volume><fpage>166</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1002/stem.160166</pub-id><?supplied-pmid 9617892?><pub-id pub-id-type="pmid">9617892</pub-id></element-citation></ref><ref id="B7-vaccines-08-00098"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mombaerts</surname><given-names>P.</given-names></name><name><surname>Iacomini</surname><given-names>J.</given-names></name><name><surname>Johnson</surname><given-names>R.S.</given-names></name><name><surname>Herrup</surname><given-names>K.</given-names></name><name><surname>Tonegawa</surname><given-names>S.</given-names></name><name><surname>Papaioannou</surname><given-names>V.E.</given-names></name></person-group><article-title>RAG-1-deficient mice have no mature B and T lymphocytes</article-title><source>Cell</source><year>1992</year><volume>68</volume><fpage>869</fpage><lpage>877</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(92)90030-G</pub-id><pub-id pub-id-type="pmid">1547488</pub-id></element-citation></ref><ref id="B8-vaccines-08-00098"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shinkai</surname><given-names>Y.</given-names></name><name><surname>Rathbun</surname><given-names>G.</given-names></name><name><surname>Lam</surname><given-names>K.-P.</given-names></name><name><surname>Oltz</surname><given-names>E.M.</given-names></name><name><surname>Stewart</surname><given-names>V.</given-names></name><name><surname>Mendelsohn</surname><given-names>M.</given-names></name><name><surname>Charron</surname><given-names>J.</given-names></name><name><surname>Datta</surname><given-names>M.</given-names></name><name><surname>Young</surname><given-names>F.</given-names></name><name><surname>Stall</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement</article-title><source>Cell</source><year>1992</year><volume>68</volume><fpage>855</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(92)90029-C</pub-id><pub-id pub-id-type="pmid">1547487</pub-id></element-citation></ref><ref id="B9-vaccines-08-00098"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shultz</surname><given-names>L.D.</given-names></name><name><surname>Lang</surname><given-names>P.A.</given-names></name><name><surname>Christianson</surname><given-names>S.W.</given-names></name><name><surname>Gott</surname><given-names>B.</given-names></name><name><surname>Lyons</surname><given-names>B.</given-names></name><name><surname>Umeda</surname><given-names>S.</given-names></name><name><surname>Leiter</surname><given-names>E.</given-names></name><name><surname>Hesselton</surname><given-names>R.</given-names></name><name><surname>Wagar</surname><given-names>E.J.</given-names></name><name><surname>Leif</surname><given-names>J.H.</given-names></name><etal/></person-group><article-title>NOD/LtSz-Rag1null mice: An immunodeficient and radioresistant model for engraftment of human hematolymphoid cells, HIV infection, and adoptive transfer of NOD mouse diabetogenic T cells</article-title><source>J. Immunol.</source><year>2000</year><volume>164</volume><fpage>2496</fpage><lpage>2507</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.164.5.2496</pub-id><pub-id pub-id-type="pmid">10679087</pub-id></element-citation></ref><ref id="B10-vaccines-08-00098"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiSanto</surname><given-names>J.P.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>W.</given-names></name><name><surname>Guy-Grand</surname><given-names>D.</given-names></name><name><surname>Fischer</surname><given-names>A.</given-names></name><name><surname>Rajewsky</surname><given-names>K.</given-names></name></person-group><article-title>Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1995</year><volume>92</volume><fpage>377</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.2.377</pub-id><pub-id pub-id-type="pmid">7831294</pub-id></element-citation></ref><ref id="B11-vaccines-08-00098"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>M.</given-names></name><name><surname>Hiramatsu</surname><given-names>H.</given-names></name><name><surname>Kobayashi</surname><given-names>K.</given-names></name><name><surname>Suzue</surname><given-names>K.</given-names></name><name><surname>Kawahata</surname><given-names>M.</given-names></name><name><surname>Hioki</surname><given-names>K.</given-names></name><name><surname>Ueyama</surname><given-names>Y.</given-names></name><name><surname>Koyanagi</surname><given-names>Y.</given-names></name><name><surname>Sugamura</surname><given-names>K.</given-names></name><name><surname>Tsuji</surname><given-names>K.</given-names></name><etal/></person-group><article-title>NOD/SCID/gamma-c null mouse: An excellent recipient mouse model for engraftment of human cells</article-title><source>Blood</source><year>2002</year><volume>100</volume><fpage>3175</fpage><lpage>3182</lpage><pub-id pub-id-type="doi">10.1182/blood-2001-12-0207</pub-id><pub-id pub-id-type="pmid">12384415</pub-id></element-citation></ref><ref id="B12-vaccines-08-00098"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname><given-names>J.P.</given-names></name><name><surname>Blundell</surname><given-names>M.P.</given-names></name><name><surname>Lopes</surname><given-names>L.</given-names></name><name><surname>Kinnon</surname><given-names>C.</given-names></name><name><surname>DI Santo</surname><given-names>J.P.</given-names></name><name><surname>Thrasher</surname><given-names>A.J.</given-names></name></person-group><article-title>Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain</article-title><source>Br. J. Haematol.</source><year>1998</year><volume>103</volume><fpage>335</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2141.1998.00980.x</pub-id><?supplied-pmid 9827902?><pub-id pub-id-type="pmid">9827902</pub-id></element-citation></ref><ref id="B13-vaccines-08-00098"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takenaka</surname><given-names>K.</given-names></name><name><surname>Prasolava</surname><given-names>T.K.</given-names></name><name><surname>Wang</surname><given-names>J.C.Y.</given-names></name><name><surname>Mortin-Toth</surname><given-names>S.M.</given-names></name><name><surname>Khalouei</surname><given-names>S.</given-names></name><name><surname>Gan</surname><given-names>O.I.</given-names></name><name><surname>Dick</surname><given-names>J.E.</given-names></name><name><surname>Danska</surname><given-names>J.S.</given-names></name></person-group><article-title>Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells</article-title><source>Nat. Immunol.</source><year>2007</year><volume>8</volume><fpage>1313</fpage><lpage>1323</lpage><pub-id pub-id-type="doi">10.1038/ni1527</pub-id><?supplied-pmid 17982459?><pub-id pub-id-type="pmid">17982459</pub-id></element-citation></ref><ref id="B14-vaccines-08-00098"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strowig</surname><given-names>T.</given-names></name><name><surname>Rongvaux</surname><given-names>A.</given-names></name><name><surname>Rathinam</surname><given-names>C.</given-names></name><name><surname>Takizawa</surname><given-names>H.</given-names></name><name><surname>Borsotti</surname><given-names>C.</given-names></name><name><surname>Philbrick</surname><given-names>W.</given-names></name><name><surname>Eynon</surname><given-names>E.E.</given-names></name><name><surname>Manz</surname><given-names>M.G.</given-names></name><name><surname>Flavell</surname><given-names>R.A.</given-names></name></person-group><article-title>Transgenic expression of human signal regulatory protein alpha in Rag2<sup>&#x02212;/&#x02212;</sup>&#x003b3;c<sup>&#x02212;/&#x02212;</sup> mice improves engraftment of human hematopoietic cells in humanized mice</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2011</year><volume>108</volume><fpage>13218</fpage><lpage>13223</lpage><pub-id pub-id-type="doi">10.1073/pnas.1109769108</pub-id><?supplied-pmid 21788509?><pub-id pub-id-type="pmid">21788509</pub-id></element-citation></ref><ref id="B15-vaccines-08-00098"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavender</surname><given-names>K.J.</given-names></name><name><surname>Pang</surname><given-names>W.W.</given-names></name><name><surname>Messer</surname><given-names>R.J.</given-names></name><name><surname>Duley</surname><given-names>A.K.</given-names></name><name><surname>Race</surname><given-names>B.</given-names></name><name><surname>Phillips</surname><given-names>K.</given-names></name><name><surname>Scott</surname><given-names>D.</given-names></name><name><surname>Peterson</surname><given-names>K.E.</given-names></name><name><surname>Chan</surname><given-names>C.K.</given-names></name><name><surname>Dittmer</surname><given-names>U.</given-names></name><etal/></person-group><article-title>BLT-humanized C57BL/6 Rag2<sup>&#x02212;/&#x02212;</sup>&#x003b3;c<sup>&#x02212;/&#x02212;</sup>CD47<sup>&#x02212;/&#x02212;</sup> mice are resistant to GVHD and develop B- and T-cell immunity to HIV infection</article-title><source>Blood</source><year>2013</year><volume>122</volume><fpage>4013</fpage><lpage>4020</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-06-506949</pub-id><?supplied-pmid 24021673?><pub-id pub-id-type="pmid">24021673</pub-id></element-citation></ref><ref id="B16-vaccines-08-00098"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolini</surname><given-names>F.E.</given-names></name><name><surname>Cashman</surname><given-names>J.D.</given-names></name><name><surname>Hogge</surname><given-names>D.E.</given-names></name><name><surname>Humphries</surname><given-names>R.K.</given-names></name><name><surname>Eaves</surname><given-names>C.J.</given-names></name></person-group><article-title>NOD/SCID mice engineered to express human IL-3, GM-CSF and Steel factor constitutively mobilize engrafted human progenitors and compromise human stem cell regeneration</article-title><source>Leukemia</source><year>2004</year><volume>18</volume><fpage>341</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2403222</pub-id><?supplied-pmid 14628073?><pub-id pub-id-type="pmid">14628073</pub-id></element-citation></ref><ref id="B17-vaccines-08-00098"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katano</surname><given-names>I.</given-names></name><name><surname>Takahashi</surname><given-names>T.</given-names></name><name><surname>Ito</surname><given-names>R.</given-names></name><name><surname>Kamisako</surname><given-names>T.</given-names></name><name><surname>Mizusawa</surname><given-names>T.</given-names></name><name><surname>Ka</surname><given-names>Y.</given-names></name><name><surname>Ogura</surname><given-names>T.</given-names></name><name><surname>Suemizu</surname><given-names>H.</given-names></name><name><surname>Kawakami</surname><given-names>Y.</given-names></name><name><surname>Ito</surname><given-names>M.</given-names></name></person-group><article-title>Predominant development of mature and functional human NK cells in a novel human IL-2-producing transgenic NOG mouse</article-title><source>J. Immunol.</source><year>2015</year><volume>194</volume><fpage>3513</fpage><lpage>3525</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1401323</pub-id><?supplied-pmid 25712215?><pub-id pub-id-type="pmid">25712215</pub-id></element-citation></ref><ref id="B18-vaccines-08-00098"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katano</surname><given-names>I.</given-names></name><name><surname>Nishime</surname><given-names>C.</given-names></name><name><surname>Ito</surname><given-names>R.</given-names></name><name><surname>Kamisako</surname><given-names>T.</given-names></name><name><surname>Mizusawa</surname><given-names>T.</given-names></name><name><surname>Ka</surname><given-names>Y.</given-names></name><name><surname>Ogura</surname><given-names>T.</given-names></name><name><surname>Suemizu</surname><given-names>H.</given-names></name><name><surname>Kawakami</surname><given-names>Y.</given-names></name><name><surname>Ito</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Long-term maintenance of peripheral blood derived human NK cells in a novel human IL-15&#x02014;Transgenic NOG mouse</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>17230</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-17442-7</pub-id><pub-id pub-id-type="pmid">29222435</pub-id></element-citation></ref><ref id="B19-vaccines-08-00098"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shultz</surname><given-names>L.D.</given-names></name><name><surname>Saito</surname><given-names>Y.</given-names></name><name><surname>Najima</surname><given-names>Y.</given-names></name><name><surname>Tanaka</surname><given-names>S.</given-names></name><name><surname>Ochi</surname><given-names>T.</given-names></name><name><surname>Tomizawa</surname><given-names>M.</given-names></name><name><surname>Doi</surname><given-names>T.</given-names></name><name><surname>Sone</surname><given-names>A.</given-names></name><name><surname>Suzuki</surname><given-names>N.</given-names></name><name><surname>Fujiwara</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>13022</fpage><lpage>13027</lpage><pub-id pub-id-type="doi">10.1073/pnas.1000475107</pub-id><pub-id pub-id-type="pmid">20615947</pub-id></element-citation></ref><ref id="B20-vaccines-08-00098"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>M.</given-names></name><name><surname>Takahashi</surname><given-names>T.</given-names></name><name><surname>Katano</surname><given-names>I.</given-names></name><name><surname>Ito</surname><given-names>R.</given-names></name><name><surname>Ito</surname><given-names>M.</given-names></name><name><surname>Harigae</surname><given-names>H.</given-names></name><name><surname>Ishii</surname><given-names>N.</given-names></name><name><surname>Sugamura</surname><given-names>K.</given-names></name></person-group><article-title>Induction of human humoral immune responses in a novel HLA-DR-expressing transgenic NOD/Shi-scid/&#x003b3;cnull mouse</article-title><source>Int. Immunol.</source><year>2012</year><volume>24</volume><fpage>243</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxs045</pub-id><pub-id pub-id-type="pmid">22402880</pub-id></element-citation></ref><ref id="B21-vaccines-08-00098"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosier</surname><given-names>D.E.</given-names></name><name><surname>Gulizia</surname><given-names>R.J.</given-names></name><name><surname>Baird</surname><given-names>S.M.</given-names></name><name><surname>Wilson</surname><given-names>D.B.</given-names></name></person-group><article-title>Transfer of a functional human immune system to mice with severe combined immunodeficiency</article-title><source>Nature</source><year>1988</year><volume>335</volume><fpage>256</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1038/335256a0</pub-id><pub-id pub-id-type="pmid">2970594</pub-id></element-citation></ref><ref id="B22-vaccines-08-00098"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tary-Lehmann</surname><given-names>M.</given-names></name><name><surname>Lehmann</surname><given-names>P.V.</given-names></name><name><surname>Schols</surname><given-names>D.</given-names></name><name><surname>Roncarolo</surname><given-names>M.G.</given-names></name><name><surname>Saxon</surname><given-names>A.</given-names></name></person-group><article-title>Anti-SCID mouse reactivity shapes the human CD4+ T cell repertoire in hu-PBL-SCID chimeras</article-title><source>J. Exp. Med.</source><year>1994</year><volume>180</volume><fpage>1817</fpage><lpage>1827</lpage><pub-id pub-id-type="doi">10.1084/jem.180.5.1817</pub-id><?supplied-pmid 7964463?><pub-id pub-id-type="pmid">7964463</pub-id></element-citation></ref><ref id="B23-vaccines-08-00098"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harui</surname><given-names>A.</given-names></name><name><surname>Kiertscher</surname><given-names>S.M.</given-names></name><name><surname>Roth</surname><given-names>M.D.</given-names></name></person-group><article-title>Reconstitution of huPBL-NSG mice with donor-matched dendritic cells enables antigen-specific T-cell activation</article-title><source>J. Neuroimmune Pharmacol.</source><year>2011</year><volume>6</volume><fpage>148</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1007/s11481-010-9223-x</pub-id><?supplied-pmid 20532647?><pub-id pub-id-type="pmid">20532647</pub-id></element-citation></ref><ref id="B24-vaccines-08-00098"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosier</surname><given-names>D.E.</given-names></name><name><surname>Gulizia</surname><given-names>R.J.</given-names></name><name><surname>MacIsaac</surname><given-names>P.D.</given-names></name><name><surname>Corey</surname><given-names>L.</given-names></name><name><surname>Greenberg</surname><given-names>P.D.</given-names></name></person-group><article-title>Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1993</year><volume>90</volume><fpage>2443</fpage><lpage>2447</lpage><pub-id pub-id-type="doi">10.1073/pnas.90.6.2443</pub-id><?supplied-pmid 8460155?><pub-id pub-id-type="pmid">8460155</pub-id></element-citation></ref><ref id="B25-vaccines-08-00098"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>R.</given-names></name><name><surname>Katano</surname><given-names>I.</given-names></name><name><surname>Kawai</surname><given-names>K.</given-names></name><name><surname>Hirata</surname><given-names>H.</given-names></name><name><surname>Ogura</surname><given-names>T.</given-names></name><name><surname>Kamisako</surname><given-names>T.</given-names></name><name><surname>Eto</surname><given-names>T.</given-names></name><name><surname>Ito</surname><given-names>M.</given-names></name></person-group><article-title>Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice</article-title><source>Transplantation</source><year>2009</year><volume>87</volume><fpage>1654</fpage><lpage>1658</lpage><pub-id pub-id-type="doi">10.1097/TP.0b013e3181a5cb07</pub-id><?supplied-pmid 19502956?><pub-id pub-id-type="pmid">19502956</pub-id></element-citation></ref><ref id="B26-vaccines-08-00098"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>P&#x000e9;ault</surname><given-names>B.</given-names></name><name><surname>Weissman</surname><given-names>I.</given-names></name><name><surname>Baum</surname><given-names>C.</given-names></name></person-group><article-title>Analysis of candidate human blood stem cells in &#x0201c;humanized&#x0201d; immune-deficiency SCID mice</article-title><source>Leukemia</source><year>1993</year><volume>7</volume><fpage>S98</fpage><lpage>S101</lpage><pub-id pub-id-type="pmid">7689676</pub-id></element-citation></ref><ref id="B27-vaccines-08-00098"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melkus</surname><given-names>M.W.</given-names></name><name><surname>Estes</surname><given-names>J.D.</given-names></name><name><surname>Padgett-Thomas</surname><given-names>A.</given-names></name><name><surname>Gatlin</surname><given-names>J.</given-names></name><name><surname>Denton</surname><given-names>P.W.</given-names></name><name><surname>Othieno</surname><given-names>F.A.</given-names></name><name><surname>Wege</surname><given-names>A.K.</given-names></name><name><surname>Haase</surname><given-names>A.T.</given-names></name><name><surname>Garcia</surname><given-names>J.V.</given-names></name></person-group><article-title>Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1</article-title><source>Nat. Med.</source><year>2006</year><volume>12</volume><fpage>1316</fpage><lpage>1322</lpage><pub-id pub-id-type="doi">10.1038/nm1431</pub-id><pub-id pub-id-type="pmid">17057712</pub-id></element-citation></ref><ref id="B28-vaccines-08-00098"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>S.</given-names></name><name><surname>Chang</surname><given-names>H.</given-names></name><name><surname>Sarkis</surname><given-names>P.T.N.</given-names></name><name><surname>Fikrig</surname><given-names>E.</given-names></name><name><surname>Zhu</surname><given-names>Q.</given-names></name><name><surname>Marasco</surname><given-names>W.A.</given-names></name></person-group><article-title>Humoral immune responses in humanized BLT mice immunized with West Nile virus and HIV-1 envelope proteins are largely mediated via human CD5 + B cells</article-title><source>Immunology</source><year>2011</year><volume>134</volume><fpage>419</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2567.2011.03501.x</pub-id><pub-id pub-id-type="pmid">22044090</pub-id></element-citation></ref><ref id="B29-vaccines-08-00098"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenblatt</surname><given-names>M.B.</given-names></name><name><surname>Vbranac</surname><given-names>V.</given-names></name><name><surname>Tivey</surname><given-names>T.</given-names></name><name><surname>Tsang</surname><given-names>K.</given-names></name><name><surname>Tager</surname><given-names>A.M.</given-names></name><name><surname>Aliprantis</surname><given-names>A.O.</given-names></name></person-group><article-title>Graft versus Host Disease in the Bone Marrow, Liver and Thymus Humanized Mouse Model</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e44664</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0044664</pub-id><pub-id pub-id-type="pmid">22957096</pub-id></element-citation></ref><ref id="B30-vaccines-08-00098"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wunderlich</surname><given-names>M.</given-names></name><name><surname>Chou</surname><given-names>F.-S.</given-names></name><name><surname>Link</surname><given-names>K.A.</given-names></name><name><surname>Mizukawa</surname><given-names>B.</given-names></name><name><surname>Perry</surname><given-names>R.L.</given-names></name><name><surname>Carroll</surname><given-names>M.</given-names></name><name><surname>Mulloy</surname><given-names>J.C.</given-names></name></person-group><article-title>AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3</article-title><source>Leukemia</source><year>2010</year><volume>24</volume><fpage>1785</fpage><lpage>1788</lpage><pub-id pub-id-type="doi">10.1038/leu.2010.158</pub-id><pub-id pub-id-type="pmid">20686503</pub-id></element-citation></ref><ref id="B31-vaccines-08-00098"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavender</surname><given-names>K.J.</given-names></name><name><surname>Messer</surname><given-names>R.J.</given-names></name><name><surname>Race</surname><given-names>B.</given-names></name><name><surname>Hasenkrug</surname><given-names>K.J.</given-names></name></person-group><article-title>Production of bone marrow, liver, thymus (BLT) humanized mice on the C57BL/6 Rag2<sup>&#x02212;/&#x02212;</sup>&#x003b3;c<sup>&#x02212;/&#x02212;</sup>CD47<sup>&#x02212;/&#x02212;</sup> background</article-title><source>J. Immunol. Methods</source><year>2014</year><volume>407</volume><fpage>127</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2014.04.008</pub-id><pub-id pub-id-type="pmid">24769067</pub-id></element-citation></ref><ref id="B32-vaccines-08-00098"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>D.R.</given-names></name><name><surname>Steele</surname><given-names>K.E.</given-names></name><name><surname>Shamblin</surname><given-names>J.</given-names></name><name><surname>Honko</surname><given-names>A.</given-names></name><name><surname>Johnson</surname><given-names>J.</given-names></name><name><surname>Reed</surname><given-names>C.</given-names></name><name><surname>Kennedy</surname><given-names>M.</given-names></name><name><surname>Chapman</surname><given-names>J.L.</given-names></name><name><surname>Hensley</surname><given-names>L.E.</given-names></name></person-group><article-title>The pathogenesis of Rift Valley fever virus in the mouse model</article-title><source>Virology</source><year>2010</year><volume>407</volume><fpage>256</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2010.08.016</pub-id><?supplied-pmid 20850165?><pub-id pub-id-type="pmid">20850165</pub-id></element-citation></ref><ref id="B33-vaccines-08-00098"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yun</surname><given-names>N.E.</given-names></name><name><surname>Seregin</surname><given-names>A.V.</given-names></name><name><surname>Walker</surname><given-names>D.H.</given-names></name><name><surname>Popov</surname><given-names>V.L.</given-names></name><name><surname>Walker</surname><given-names>A.G.</given-names></name><name><surname>Smith</surname><given-names>J.N.J.K.</given-names></name><name><surname>Miller</surname><given-names>M.</given-names></name><name><surname>de la Torre</surname><given-names>J.C.</given-names></name><name><surname>Smith</surname><given-names>J.N.J.K.</given-names></name><name><surname>Borisevich</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Mice lacking functional STAT1 are highly susceptible to lethal infection with Lassa virus</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>10908</fpage><lpage>10911</lpage><pub-id pub-id-type="doi">10.1128/JVI.01433-13</pub-id><?supplied-pmid 23903830?><pub-id pub-id-type="pmid">23903830</pub-id></element-citation></ref><ref id="B34-vaccines-08-00098"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oestereich</surname><given-names>L.</given-names></name><name><surname>L&#x000fc;dtke</surname><given-names>A.</given-names></name><name><surname>Wurr</surname><given-names>S.</given-names></name><name><surname>Rieger</surname><given-names>T.</given-names></name><name><surname>Mu&#x000f1;oz-Fontela</surname><given-names>C.</given-names></name><name><surname>G&#x000fc;nther</surname><given-names>S.</given-names></name></person-group><article-title>Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model</article-title><source>Antivir. Res.</source><year>2014</year><volume>105</volume><fpage>17</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2014.02.014</pub-id><?supplied-pmid 24583123?><pub-id pub-id-type="pmid">24583123</pub-id></element-citation></ref><ref id="B35-vaccines-08-00098"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lathan</surname><given-names>R.</given-names></name><name><surname>Simon-Chazottes</surname><given-names>D.</given-names></name><name><surname>Jouvion</surname><given-names>G.</given-names></name><name><surname>Godon</surname><given-names>O.</given-names></name><name><surname>Malissen</surname><given-names>M.</given-names></name><name><surname>Flamand</surname><given-names>M.</given-names></name><name><surname>Bruhns</surname><given-names>P.</given-names></name><name><surname>Panthier</surname><given-names>J.J.</given-names></name></person-group><article-title>Innate Immune Basis for Rift Valley Fever Susceptibility in Mouse Models</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1038/s41598-017-07543-8</pub-id><pub-id pub-id-type="pmid">28127051</pub-id></element-citation></ref><ref id="B36-vaccines-08-00098"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradfute</surname><given-names>S.B.</given-names></name><name><surname>Warfield</surname><given-names>K.L.</given-names></name><name><surname>Bray</surname><given-names>M.</given-names></name></person-group><article-title>Mouse models for filovirus infections</article-title><source>Viruses</source><year>2012</year><volume>4</volume><fpage>1477</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.3390/v4091477</pub-id><pub-id pub-id-type="pmid">23170168</pub-id></element-citation></ref><ref id="B37-vaccines-08-00098"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escudero-P&#x000e9;rez</surname><given-names>B.</given-names></name><name><surname>Ruibal</surname><given-names>P.</given-names></name><name><surname>Rottstegge</surname><given-names>M.</given-names></name><name><surname>L&#x000fc;dtke</surname><given-names>A.</given-names></name><name><surname>Port</surname><given-names>J.R.</given-names></name><name><surname>Hartmann</surname><given-names>K.</given-names></name><name><surname>G&#x000f3;mez-Medina</surname><given-names>S.</given-names></name><name><surname>M&#x000fc;ller-Guhl</surname><given-names>J.</given-names></name><name><surname>Nelson</surname><given-names>E.V.</given-names></name><name><surname>Krasemann</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Comparative pathogenesis of Ebola virus and Reston virus infection in humanized mice</article-title><source>JCI Insight</source><year>2019</year><volume>4</volume><pub-id pub-id-type="doi">10.1172/jci.insight.126070</pub-id></element-citation></ref><ref id="B38-vaccines-08-00098"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000fc;dtke</surname><given-names>A.</given-names></name><name><surname>Oestereich</surname><given-names>L.</given-names></name><name><surname>Ruibal</surname><given-names>P.</given-names></name><name><surname>Wurr</surname><given-names>S.</given-names></name><name><surname>Pallasch</surname><given-names>E.</given-names></name><name><surname>Bockholt</surname><given-names>S.</given-names></name><name><surname>Ip</surname><given-names>W.H.</given-names></name><name><surname>Rieger</surname><given-names>T.</given-names></name><name><surname>G&#x000f3;mez-Medina</surname><given-names>S.</given-names></name><name><surname>Stocking</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Ebola virus disease in mice transplanted with human hematopoietic stem cells</article-title><source>J. Virol.</source><year>2015</year><volume>89</volume><fpage>4700</fpage><lpage>4704</lpage><pub-id pub-id-type="doi">10.1128/JVI.03546-14</pub-id><pub-id pub-id-type="pmid">25673711</pub-id></element-citation></ref><ref id="B39-vaccines-08-00098"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spengler</surname><given-names>J.R.</given-names></name><name><surname>Saturday</surname><given-names>G.</given-names></name><name><surname>Lavender</surname><given-names>K.J.</given-names></name><name><surname>Martellaro</surname><given-names>C.</given-names></name><name><surname>Keck</surname><given-names>J.G.</given-names></name><name><surname>Nichol</surname><given-names>S.T.</given-names></name><name><surname>Spiropoulou</surname><given-names>C.F.</given-names></name><name><surname>Feldmann</surname><given-names>H.</given-names></name><name><surname>Prescott</surname><given-names>J.</given-names></name></person-group><article-title>Severity of Disease in Humanized Mice Infected with Ebola Virus or Reston Virus Is Associated with Magnitude of Early Viral Replication in Liver</article-title><source>J. Infect. Dis.</source><year>2017</year><volume>217</volume><fpage>58</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1093/infdis/jix562</pub-id><pub-id pub-id-type="pmid">29087482</pub-id></element-citation></ref><ref id="B40-vaccines-08-00098"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bird</surname><given-names>B.H.</given-names></name><name><surname>Spengler</surname><given-names>J.R.</given-names></name><name><surname>Chakrabarti</surname><given-names>A.K.</given-names></name><name><surname>Khristova</surname><given-names>M.L.</given-names></name><name><surname>Sealy</surname><given-names>T.K.</given-names></name><name><surname>Coleman-McCray</surname><given-names>J.D.</given-names></name><name><surname>Martin</surname><given-names>B.E.</given-names></name><name><surname>Dodd</surname><given-names>K.A.</given-names></name><name><surname>Goldsmith</surname><given-names>C.</given-names></name><name><surname>Sanders</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Humanized mouse model of Ebola virus disease mimics immune responses in human disease</article-title><source>J. Infect. Dis.</source><year>2016</year><volume>213</volume><fpage>703</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiv538</pub-id><pub-id pub-id-type="pmid">26582961</pub-id></element-citation></ref><ref id="B41-vaccines-08-00098"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavender</surname><given-names>K.J.</given-names></name><name><surname>Williamson</surname><given-names>B.N.</given-names></name><name><surname>Saturday</surname><given-names>G.</given-names></name><name><surname>Martellaro</surname><given-names>C.</given-names></name><name><surname>Griffin</surname><given-names>A.</given-names></name><name><surname>Hasenkrug</surname><given-names>K.J.</given-names></name><name><surname>Feldmann</surname><given-names>H.</given-names></name><name><surname>Prescott</surname><given-names>J.</given-names></name></person-group><article-title>Pathogenicity of Ebola and Marburg Viruses Is Associated with Differential Activation of the Myeloid Compartment in Humanized Triple Knockout-Bone Marrow, Liver, and Thymus Mice</article-title><source>J. Infect. Dis.</source><year>2018</year><volume>218</volume><fpage>S409</fpage><lpage>S417</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiy269</pub-id><pub-id pub-id-type="pmid">30085162</pub-id></element-citation></ref><ref id="B42-vaccines-08-00098"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spengler</surname><given-names>J.R.</given-names></name><name><surname>Kelly Keating</surname><given-names>M.</given-names></name><name><surname>McElroy</surname><given-names>A.K.</given-names></name><name><surname>Zivcec</surname><given-names>M.</given-names></name><name><surname>Coleman-McCray</surname><given-names>J.D.</given-names></name><name><surname>Harmon</surname><given-names>J.R.</given-names></name><name><surname>Bollweg</surname><given-names>B.C.</given-names></name><name><surname>Goldsmith</surname><given-names>C.S.</given-names></name><name><surname>Bergeron</surname><given-names>&#x000c9;.</given-names></name><name><surname>Keck</surname><given-names>J.G.</given-names></name><etal/></person-group><article-title>Crimean-Congo Hemorrhagic Fever in Humanized Mice Reveals Glial Cells as Primary Targets of Neurological Infection</article-title><source>J. Infect. Dis.</source><year>2017</year><volume>216</volume><fpage>1386</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.1093/infdis/jix215</pub-id><?supplied-pmid 28482001?><pub-id pub-id-type="pmid">28482001</pub-id></element-citation></ref><ref id="B43-vaccines-08-00098"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spengler</surname><given-names>J.R.</given-names></name><name><surname>McElroy</surname><given-names>A.K.</given-names></name><name><surname>Harmon</surname><given-names>J.R.</given-names></name><name><surname>Coleman-McCray</surname><given-names>J.D.</given-names></name><name><surname>Welch</surname><given-names>S.R.</given-names></name><name><surname>Keck</surname><given-names>J.G.</given-names></name><name><surname>Nichol</surname><given-names>S.T.</given-names></name><name><surname>Spiropoulou</surname><given-names>C.F.</given-names></name></person-group><article-title>Human immune cell engraftment does not alter development of severe acute Rift Valley fever in mice</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><elocation-id>e0201104</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0201104</pub-id><?supplied-pmid 30028878?><pub-id pub-id-type="pmid">30028878</pub-id></element-citation></ref><ref id="B44-vaccines-08-00098"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilic</surname><given-names>E.</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>D.H.</given-names></name><name><surname>Kurth</surname><given-names>A.</given-names></name><name><surname>Kobak</surname><given-names>L.</given-names></name><name><surname>Nitsche</surname><given-names>A.</given-names></name><name><surname>Raftery</surname><given-names>M.J.</given-names></name><name><surname>Sch&#x000f6;nrich</surname><given-names>G.</given-names></name><name><surname>Witkowski</surname><given-names>P.</given-names></name><name><surname>K&#x000fc;hl</surname><given-names>A.A.</given-names></name><name><surname>Voigt</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Hantavirus-induced pathogenesis in mice with a humanized immune system</article-title><source>J. Gen. Virol.</source><year>2015</year><volume>96</volume><fpage>1258</fpage><lpage>1263</lpage><pub-id pub-id-type="pmid">25678530</pub-id></element-citation></ref><ref id="B45-vaccines-08-00098"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rougeron</surname><given-names>V.</given-names></name><name><surname>Feldmann</surname><given-names>H.</given-names></name><name><surname>Grard</surname><given-names>G.</given-names></name><name><surname>Becker</surname><given-names>S.</given-names></name><name><surname>Leroy</surname><given-names>E.M.</given-names></name></person-group><article-title>Ebola and Marburg haemorrhagic fever</article-title><source>J. Clin. Virol.</source><year>2015</year><volume>64</volume><fpage>111</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2015.01.014</pub-id><?supplied-pmid 25660265?><pub-id pub-id-type="pmid">25660265</pub-id></element-citation></ref><ref id="B46-vaccines-08-00098"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegert</surname><given-names>R.</given-names></name><name><surname>Shu</surname><given-names>H.-L.</given-names></name><name><surname>Slenczka</surname><given-names>W.</given-names></name><name><surname>Peters</surname><given-names>D.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>G.</given-names></name></person-group><article-title>Zur &#x000c4;tiologie einer unbekannten, von Affen ausgegangenen menschlichen Infektionskrankheit</article-title><source>DMW-Dtsch. Med. Wochenschr.</source><year>1967</year><volume>92</volume><fpage>2341</fpage><lpage>2343</lpage><pub-id pub-id-type="doi">10.1055/s-0028-1106144</pub-id><?supplied-pmid 4294540?><pub-id pub-id-type="pmid">4294540</pub-id></element-citation></ref><ref id="B47-vaccines-08-00098"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gedigk</surname><given-names>P.</given-names></name><name><surname>Bechtelsheimer</surname><given-names>H.</given-names></name><name><surname>Korb</surname><given-names>G.</given-names></name></person-group><article-title>Die pathologische Anatomie der &#x0201c;Marburg-Virus&#x0201d;-Krankheit (sog. &#x0201c;Marburger Affenkrankheit&#x0201d;)</article-title><source>DMW-Dtsch. Med. Wochenschr.</source><year>1968</year><volume>93</volume><fpage>590</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1055/s-0028-1105101</pub-id><?supplied-pmid 4966283?><pub-id pub-id-type="pmid">4966283</pub-id></element-citation></ref><ref id="B48-vaccines-08-00098"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martini</surname><given-names>G.A.</given-names></name><name><surname>Knauff</surname><given-names>H.G.</given-names></name><name><surname>Schmidt</surname><given-names>H.A.</given-names></name><name><surname>Mayer</surname><given-names>G.</given-names></name><name><surname>Baltzer</surname><given-names>G.</given-names></name></person-group><article-title>&#x000dc;ber eine bisher unbekannte, von Affen eingeschleppte Infektionskrankheit: Marburg-Virus-Krankheit</article-title><source>DMW-Dtsch. Med. Wochenschr.</source><year>1968</year><volume>93</volume><fpage>559</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1055/s-0028-1105098</pub-id></element-citation></ref><ref id="B49-vaccines-08-00098"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>K.</given-names></name><name><surname>Lange</surname><given-names>J.</given-names></name><name><surname>Webb</surname><given-names>P.</given-names></name><name><surname>Murphy</surname><given-names>F.</given-names></name></person-group><article-title>Isolation and partial characterisation of a new virus causing acute h&#x000e6;morrhagic fever in Zaire</article-title><source>Lancet</source><year>1977</year><volume>309</volume><fpage>569</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(77)92000-1</pub-id></element-citation></ref><ref id="B50-vaccines-08-00098"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowen</surname><given-names>E.T.W.</given-names></name><name><surname>Lloyd</surname><given-names>G.</given-names></name><name><surname>Harris</surname><given-names>W.J.</given-names></name><name><surname>Platt</surname><given-names>G.S.</given-names></name><name><surname>Baskerville</surname><given-names>A.</given-names></name><name><surname>Vella</surname><given-names>E.E.</given-names></name></person-group><article-title>Viral h&#x000e6;morrhagic fever in southern sudan and northern zaire: Preliminary studies on the aetiological agent</article-title><source>Lancet</source><year>1977</year><volume>309</volume><fpage>571</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(77)92001-3</pub-id></element-citation></ref><ref id="B51-vaccines-08-00098"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pattyn</surname><given-names>S.</given-names></name><name><surname>Jacob</surname><given-names>W.</given-names></name><name><surname>Van der Groen</surname><given-names>G.</given-names></name><name><surname>Piot</surname><given-names>P.</given-names></name><name><surname>Courteille</surname><given-names>G.</given-names></name></person-group><article-title>Isolation OF Marburg-Like virus from a case of h&#x000e6;morrhagic fever in zaire</article-title><source>Lancet</source><year>1977</year><volume>309</volume><fpage>573</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(77)92002-5</pub-id></element-citation></ref><ref id="B52-vaccines-08-00098"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>M.</given-names></name><name><surname>Mahanty</surname><given-names>S.</given-names></name><name><surname>Ahmed</surname><given-names>R.</given-names></name><name><surname>Rollin</surname><given-names>P.E.</given-names></name></person-group><article-title>Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro</article-title><source>Virology</source><year>2001</year><volume>284</volume><fpage>20</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1006/viro.2001.0836</pub-id><?supplied-pmid 11352664?><pub-id pub-id-type="pmid">11352664</pub-id></element-citation></ref><ref id="B53-vaccines-08-00098"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosio</surname><given-names>C.M.</given-names></name><name><surname>Aman</surname><given-names>M.J.</given-names></name><name><surname>Grogan</surname><given-names>C.</given-names></name><name><surname>Hogan</surname><given-names>R.</given-names></name><name><surname>Ruthel</surname><given-names>G.</given-names></name><name><surname>Negley</surname><given-names>D.</given-names></name><name><surname>Mohamadzadeh</surname><given-names>M.</given-names></name><name><surname>Bavari</surname><given-names>S.</given-names></name><name><surname>Schmaljohn</surname><given-names>A.</given-names></name></person-group><article-title>Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation</article-title><source>J. Infect. Dis.</source><year>2003</year><volume>188</volume><fpage>1630</fpage><lpage>1638</lpage><pub-id pub-id-type="doi">10.1086/379199</pub-id><?supplied-pmid 14639532?><pub-id pub-id-type="pmid">14639532</pub-id></element-citation></ref><ref id="B54-vaccines-08-00098"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahanty</surname><given-names>S.</given-names></name><name><surname>Hutchinson</surname><given-names>K.</given-names></name><name><surname>Agarwal</surname><given-names>S.</given-names></name><name><surname>McRae</surname><given-names>M.</given-names></name><name><surname>Rollin</surname><given-names>P.E.</given-names></name><name><surname>Pulendran</surname><given-names>B.</given-names></name></person-group><article-title>Cutting edge: Impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses</article-title><source>J. Immunol.</source><year>2003</year><volume>170</volume><fpage>2797</fpage><lpage>2801</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.170.6.2797</pub-id><?supplied-pmid 12626527?><pub-id pub-id-type="pmid">12626527</pub-id></element-citation></ref><ref id="B55-vaccines-08-00098"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geisbert</surname><given-names>T.W.</given-names></name><name><surname>Hensley</surname><given-names>L.E.</given-names></name><name><surname>Larsen</surname><given-names>T.</given-names></name><name><surname>Young</surname><given-names>H.A.</given-names></name><name><surname>Reed</surname><given-names>D.S.</given-names></name><name><surname>Geisbert</surname><given-names>J.B.</given-names></name><name><surname>Scott</surname><given-names>D.P.</given-names></name><name><surname>Kagan</surname><given-names>E.</given-names></name><name><surname>Jahrling</surname><given-names>P.B.</given-names></name><name><surname>Davis</surname><given-names>K.J.</given-names></name><etal/></person-group><article-title>Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: Evidence that dendritic cells are early and sustained targets of infection</article-title><source>Am. J. Pathol.</source><year>2003</year><volume>163</volume><fpage>2347</fpage><lpage>2370</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)63591-2</pub-id><pub-id pub-id-type="pmid">14633608</pub-id></element-citation></ref><ref id="B56-vaccines-08-00098"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spengler</surname><given-names>J.R.</given-names></name><name><surname>Prescott</surname><given-names>J.</given-names></name><name><surname>Feldmann</surname><given-names>H.</given-names></name><name><surname>Spiropoulou</surname><given-names>C.F.</given-names></name></person-group><article-title>Human immune system mouse models of Ebola virus infection</article-title><source>Curr. Opin. Virol.</source><year>2017</year><volume>25</volume><fpage>90</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2017.07.028</pub-id><?supplied-pmid 28810165?><pub-id pub-id-type="pmid">28810165</pub-id></element-citation></ref><ref id="B57-vaccines-08-00098"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douam</surname><given-names>F.</given-names></name><name><surname>Ploss</surname><given-names>A.</given-names></name></person-group><article-title>The use of humanized mice for studies of viral pathogenesis and immunity</article-title><source>Curr. Opin. Virol.</source><year>2018</year><volume>29</volume><fpage>62</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2018.03.003</pub-id><pub-id pub-id-type="pmid">29604551</pub-id></element-citation></ref><ref id="B58-vaccines-08-00098"><label>58.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>L&#x000fc;dtke</surname><given-names>A.</given-names></name></person-group><source>Role of Dendritic Cells on Ebola Virus Immunity and Dissemination</source><publisher-name>Staats-und Universit&#x000e4;tsbibliothek Hamburg</publisher-name><publisher-loc>Hamburg, Germany</publisher-loc><year>2016</year></element-citation></ref><ref id="B59-vaccines-08-00098"><label>59.</label><element-citation publication-type="journal"><article-title>Epidemiologic Notes and Reports Update: Filovirus Infection in Animal Handlers</article-title><source>MMWR</source><year>1990</year><volume>39</volume><fpage>221</fpage><pub-id pub-id-type="pmid">2107388</pub-id></element-citation></ref><ref id="B60-vaccines-08-00098"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jahrling</surname><given-names>P.B.</given-names></name><name><surname>Geisbert</surname><given-names>T.W.</given-names></name><name><surname>Jaax</surname><given-names>N.K.</given-names></name><name><surname>Hanes</surname><given-names>M.A.</given-names></name><name><surname>Ksiazek</surname><given-names>T.G.</given-names></name><name><surname>Peters</surname><given-names>C.J.</given-names></name></person-group><article-title>Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989&#x02013;1990 U.S. epizootic</article-title><source>Arch. Virol. Suppl.</source><year>1996</year><volume>11</volume><fpage>115</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">8800793</pub-id></element-citation></ref><ref id="B61-vaccines-08-00098"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Formenty</surname><given-names>P.</given-names></name><name><surname>Boesch</surname><given-names>C.</given-names></name><name><surname>Wyers</surname><given-names>M.</given-names></name><name><surname>Steiner</surname><given-names>C.</given-names></name><name><surname>Donati</surname><given-names>F.</given-names></name><name><surname>Dind</surname><given-names>F.</given-names></name><name><surname>Walker</surname><given-names>F.</given-names></name><name><surname>Le Guenno</surname><given-names>B.</given-names></name></person-group><article-title>Ebola virus outbreak among wild chimpanzees living in a rain forest of C&#x000f4;te d&#x02019;Ivoire</article-title><source>J. Infect. Dis.</source><year>1999</year><volume>179</volume><fpage>S120</fpage><lpage>S126</lpage><pub-id pub-id-type="doi">10.1086/514296</pub-id><pub-id pub-id-type="pmid">9988175</pub-id></element-citation></ref><ref id="B62-vaccines-08-00098"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wauquier</surname><given-names>N.</given-names></name><name><surname>Becquart</surname><given-names>P.</given-names></name><name><surname>Padilla</surname><given-names>C.</given-names></name><name><surname>Baize</surname><given-names>S.</given-names></name><name><surname>Leroy</surname><given-names>E.M.</given-names></name></person-group><article-title>Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis</article-title><source>PLoS Negl. Trop. Dis.</source><year>2010</year><volume>4</volume><elocation-id>e837</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0000837</pub-id><pub-id pub-id-type="pmid">20957152</pub-id></element-citation></ref><ref id="B63-vaccines-08-00098"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahanty</surname><given-names>S.</given-names></name><name><surname>Bray</surname><given-names>M.</given-names></name></person-group><article-title>Pathogenesis of filoviral haemorrhagic fevers</article-title><source>Lancet Infect. Dis.</source><year>2004</year><volume>4</volume><fpage>487</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(04)01103-X</pub-id><pub-id pub-id-type="pmid">15288821</pub-id></element-citation></ref><ref id="B64-vaccines-08-00098"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villinger</surname><given-names>F.</given-names></name><name><surname>Rollin</surname><given-names>P.E.</given-names></name><name><surname>Brar</surname><given-names>S.S.</given-names></name><name><surname>Chikkala</surname><given-names>N.F.</given-names></name><name><surname>Winter</surname><given-names>J.</given-names></name><name><surname>Sundstrom</surname><given-names>J.B.</given-names></name><name><surname>Zaki</surname><given-names>S.R.</given-names></name><name><surname>Swanepoel</surname><given-names>R.</given-names></name><name><surname>Ansari</surname><given-names>A.A.</given-names></name><name><surname>Peters</surname><given-names>C.J.</given-names></name></person-group><article-title>Markedly Elevated Levels of Interferon (IFN)-&#x003b3;, IFN-&#x003b1;, Interleukin (IL)-2, IL-10, and Tumor Necrosis Factor-&#x003b1; Associated with Fatal Ebola Virus Infection</article-title><source>J. Infect. Dis.</source><year>1999</year><volume>179</volume><fpage>S188</fpage><lpage>S191</lpage><pub-id pub-id-type="doi">10.1086/514283</pub-id><?supplied-pmid 9988183?><pub-id pub-id-type="pmid">9988183</pub-id></element-citation></ref><ref id="B65-vaccines-08-00098"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerber</surname><given-names>R.</given-names></name><name><surname>Krumkamp</surname><given-names>R.</given-names></name><name><surname>Korva</surname><given-names>M.</given-names></name><name><surname>Rieger</surname><given-names>T.</given-names></name><name><surname>Wurr</surname><given-names>S.</given-names></name><name><surname>Duraffour</surname><given-names>S.</given-names></name><name><surname>Oestereich</surname><given-names>L.</given-names></name><name><surname>Gabriel</surname><given-names>M.</given-names></name><name><surname>Sissoko</surname><given-names>D.</given-names></name><name><surname>Anglaret</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Kinetics of Soluble Mediators of the Host Response in Ebola Virus Disease</article-title><source>J. Infect. Dis.</source><year>2018</year><volume>218</volume><fpage>S496</fpage><lpage>S503</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiy429</pub-id><?supplied-pmid 30101349?><pub-id pub-id-type="pmid">30101349</pub-id></element-citation></ref><ref id="B66-vaccines-08-00098"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bente</surname><given-names>D.A.</given-names></name><name><surname>Forrester</surname><given-names>N.L.</given-names></name><name><surname>Watts</surname><given-names>D.M.</given-names></name><name><surname>McAuley</surname><given-names>A.J.</given-names></name><name><surname>Whitehouse</surname><given-names>C.A.</given-names></name><name><surname>Bray</surname><given-names>M.</given-names></name></person-group><article-title>Crimean-Congo hemorrhagic fever: History, epidemiology, pathogenesis, clinical syndrome and genetic diversity</article-title><source>Antivir. Res.</source><year>2013</year><volume>100</volume><fpage>159</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2013.07.006</pub-id><?supplied-pmid 23906741?><pub-id pub-id-type="pmid">23906741</pub-id></element-citation></ref><ref id="B67-vaccines-08-00098"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zivcec</surname><given-names>M.</given-names></name><name><surname>Safronetz</surname><given-names>D.</given-names></name><name><surname>Scott</surname><given-names>D.</given-names></name><name><surname>Robertson</surname><given-names>S.</given-names></name><name><surname>Ebihara</surname><given-names>H.</given-names></name><name><surname>Feldmann</surname><given-names>H.</given-names></name></person-group><article-title>Lethal Crimean-Congo hemorrhagic fever virus infection in interferon &#x003b1;/&#x003b2; receptor knockout mice is associated with high viral loads, pro-inflammatory responses and coagulopathy</article-title><source>J. Infect. Dis.</source><year>2013</year><volume>207</volume><fpage>1909</fpage><lpage>1921</lpage><pub-id pub-id-type="doi">10.1093/infdis/jit061</pub-id><?supplied-pmid 23417661?><pub-id pub-id-type="pmid">23417661</pub-id></element-citation></ref><ref id="B68-vaccines-08-00098"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bente</surname><given-names>D.A.</given-names></name><name><surname>Alimonti</surname><given-names>J.B.</given-names></name><name><surname>Shieh</surname><given-names>W.</given-names></name><name><surname>Camus</surname><given-names>G.</given-names></name><name><surname>Str&#x000f6;her</surname><given-names>U.</given-names></name><name><surname>Zaki</surname><given-names>S.</given-names></name><name><surname>Jones</surname><given-names>S.M.</given-names></name><name><surname>Stroher</surname><given-names>U.</given-names></name><name><surname>Wung-Shu</surname><given-names>S.</given-names></name></person-group><article-title>Pathogenesis and Immune Response of Crimean-Congo Hemorrhagic Fever Virus in a STAT-1 Knockout Mouse Model</article-title><source>J. Virol.</source><year>2010</year><volume>84</volume><fpage>11089</fpage><lpage>11100</lpage><pub-id pub-id-type="doi">10.1128/JVI.01383-10</pub-id><pub-id pub-id-type="pmid">20739514</pub-id></element-citation></ref><ref id="B69-vaccines-08-00098"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindquist</surname><given-names>M.E.</given-names></name><name><surname>Zeng</surname><given-names>X.</given-names></name><name><surname>Altamura</surname><given-names>L.A.</given-names></name><name><surname>Daye</surname><given-names>S.P.</given-names></name><name><surname>Delp</surname><given-names>K.L.</given-names></name><name><surname>Blancett</surname><given-names>C.</given-names></name><name><surname>Coffin</surname><given-names>K.M.</given-names></name><name><surname>Koehler</surname><given-names>J.W.</given-names></name><name><surname>Coyne</surname><given-names>S.</given-names></name><name><surname>Shoemaker</surname><given-names>C.J.</given-names></name><etal/></person-group><article-title>Exploring Crimean-Congo Hemorrhagic Fever Virus-Induced Hepatic Injury Using Antibody-Mediated Type I Interferon Blockade in Mice</article-title><source>J. Virol.</source><year>2018</year><volume>92</volume><fpage>e01018</fpage><lpage>e01083</lpage><pub-id pub-id-type="doi">10.1128/JVI.01083-18</pub-id><pub-id pub-id-type="pmid">30068645</pub-id></element-citation></ref><ref id="B70-vaccines-08-00098"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golden</surname><given-names>J.W.</given-names></name><name><surname>Shoemaker</surname><given-names>C.J.</given-names></name><name><surname>Lindquist</surname><given-names>M.E.</given-names></name><name><surname>Zeng</surname><given-names>X.</given-names></name><name><surname>Daye</surname><given-names>S.P.</given-names></name><name><surname>Williams</surname><given-names>J.A.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Coffin</surname><given-names>K.M.</given-names></name><name><surname>Olschner</surname><given-names>S.</given-names></name><name><surname>Flusin</surname><given-names>O.</given-names></name><etal/></person-group><article-title>GP38-targeting monoclonal antibodies protect adult mice against lethal Crimean-Congo hemorrhagic fever virus infection</article-title><source>Sci. Adv.</source><year>2019</year><volume>5</volume><fpage>eaaw9535</fpage><pub-id pub-id-type="doi">10.1126/sciadv.aaw9535</pub-id><pub-id pub-id-type="pmid">31309159</pub-id></element-citation></ref><ref id="B71-vaccines-08-00098"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Abri</surname><given-names>S.S.</given-names></name><name><surname>Hewson</surname><given-names>R.</given-names></name><name><surname>Al-Kindi</surname><given-names>H.</given-names></name><name><surname>Al-Abaidani</surname><given-names>I.</given-names></name><name><surname>Al-Jardani</surname><given-names>A.</given-names></name><name><surname>Al-Maani</surname><given-names>A.</given-names></name><name><surname>Almahrouqi</surname><given-names>S.</given-names></name><name><surname>Atkinson</surname><given-names>B.</given-names></name><name><surname>Al-Wahaibi</surname><given-names>A.</given-names></name><name><surname>Al-Rawahi</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Clinical and molecular epidemiology of Crimean-Congo hemorrhagic fever in Oman</article-title><source>PLoS Negl. Trop. Dis.</source><year>2019</year><volume>19</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0007100</pub-id></element-citation></ref><ref id="B72-vaccines-08-00098"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chevalier</surname><given-names>V.</given-names></name><name><surname>P&#x000e9;pin</surname><given-names>M.</given-names></name><name><surname>Plee</surname><given-names>L.</given-names></name><name><surname>Lancelot</surname><given-names>R.</given-names></name></person-group><article-title>Rift Valley fever-a threat for Europe?</article-title><source>Euro Surveill.</source><year>2010</year><volume>15</volume><fpage>18</fpage><lpage>28</lpage></element-citation></ref><ref id="B73-vaccines-08-00098"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouloy</surname><given-names>M.</given-names></name><name><surname>Janzen</surname><given-names>C.</given-names></name><name><surname>Vialat</surname><given-names>P.</given-names></name><name><surname>Khun</surname><given-names>H.</given-names></name><name><surname>Pavlovic</surname><given-names>J.</given-names></name><name><surname>Huerre</surname><given-names>M.</given-names></name><name><surname>Haller</surname><given-names>O.</given-names></name></person-group><article-title>Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs</article-title><source>J. Virol.</source><year>2001</year><volume>75</volume><fpage>1371</fpage><lpage>1377</lpage><pub-id pub-id-type="doi">10.1128/JVI.75.3.1371-1377.2001</pub-id><?supplied-pmid 11152510?><pub-id pub-id-type="pmid">11152510</pub-id></element-citation></ref><ref id="B74-vaccines-08-00098"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kruger</surname><given-names>D.H.</given-names></name><name><surname>Figueiredo</surname><given-names>L.T.M.</given-names></name><name><surname>Song</surname><given-names>J.W.</given-names></name><name><surname>Klempa</surname><given-names>B.</given-names></name></person-group><article-title>Hantaviruses-Globally emerging pathogens</article-title><source>J. Clin. Virol.</source><year>2015</year><volume>64</volume><fpage>128</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2014.08.033</pub-id><?supplied-pmid 25453325?><pub-id pub-id-type="pmid">25453325</pub-id></element-citation></ref><ref id="B75-vaccines-08-00098"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prescott</surname><given-names>J.B.</given-names></name><name><surname>Hall</surname><given-names>P.R.</given-names></name><name><surname>Bondu-hawkins</surname><given-names>V.S.</given-names></name><name><surname>Ye</surname><given-names>C.</given-names></name><name><surname>Hjelle</surname><given-names>B.</given-names></name></person-group><article-title>Early Innate Immune Responses to Sin Nombre Hantavirus Occur Independently of IFN Regulatory Factor 3, and Viral Entry</article-title><source>J. Immunol.</source><year>2007</year><volume>179</volume><fpage>1796</fpage><lpage>1802</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.179.3.1796</pub-id><?supplied-pmid 17641046?><pub-id pub-id-type="pmid">17641046</pub-id></element-citation></ref><ref id="B76-vaccines-08-00098"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hensley</surname><given-names>L.E.</given-names></name><name><surname>Alves</surname><given-names>D.A.</given-names></name><name><surname>Geisbert</surname><given-names>J.B.</given-names></name><name><surname>Fritz</surname><given-names>E.A.</given-names></name><name><surname>Reed</surname><given-names>C.</given-names></name><name><surname>Larsen</surname><given-names>T.</given-names></name><name><surname>Geisbert</surname><given-names>T.W.</given-names></name></person-group><article-title>Pathogenesis of marburg hemorrhagic fever in cynomolgus macaques</article-title><source>J. Infect. Dis.</source><year>2011</year><volume>204</volume><fpage>1021</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1093/infdis/jir339</pub-id><?supplied-pmid 21987738?><pub-id pub-id-type="pmid">21987738</pub-id></element-citation></ref><ref id="B77-vaccines-08-00098"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welch</surname><given-names>S.R.</given-names></name><name><surname>Ritter</surname><given-names>J.M.</given-names></name><name><surname>McElroy</surname><given-names>A.K.</given-names></name><name><surname>Harmon</surname><given-names>J.R.</given-names></name><name><surname>Coleman-McCray</surname><given-names>J.D.</given-names></name><name><surname>Scholte</surname><given-names>F.E.M.</given-names></name><name><surname>Kobinger</surname><given-names>G.P.</given-names></name><name><surname>Bergeron</surname><given-names>&#x000c9;.</given-names></name><name><surname>Zaki</surname><given-names>S.R.</given-names></name><name><surname>Nichol</surname><given-names>S.T.</given-names></name><etal/></person-group><article-title>Fluorescent Crimean-Congo hemorrhagic fever virus illuminates tissue tropism patterns and identifies early mononuclear phagocytic cell targets in IFNAR-/- mice</article-title><source>PLoS Pathog.</source><year>2019</year><volume>15</volume><elocation-id>e1008183</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008183</pub-id><?supplied-pmid 31790513?><pub-id pub-id-type="pmid">31790513</pub-id></element-citation></ref><ref id="B78-vaccines-08-00098"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruibal</surname><given-names>P.</given-names></name><name><surname>Oestereich</surname><given-names>L.</given-names></name><name><surname>Ludtke</surname><given-names>A.</given-names></name><name><surname>Becker-Ziaja</surname><given-names>B.</given-names></name><name><surname>Wozniak</surname><given-names>D.M.</given-names></name><name><surname>Kerber</surname><given-names>R.</given-names></name><name><surname>Korva</surname><given-names>M.</given-names></name><name><surname>Cabeza-Cabrerizo</surname><given-names>M.</given-names></name><name><surname>Bore</surname><given-names>J.A.</given-names></name><name><surname>Koundouno</surname><given-names>F.R.</given-names></name><etal/></person-group><article-title>Unique human immune signature of Ebola virus disease in Guinea</article-title><source>Nature</source><year>2016</year><volume>533</volume><fpage>100</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1038/nature17949</pub-id><pub-id pub-id-type="pmid">27147028</pub-id></element-citation></ref><ref id="B79-vaccines-08-00098"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oestereich</surname><given-names>L.</given-names></name><name><surname>L&#x000fc;dtke</surname><given-names>A.</given-names></name><name><surname>Ruibal</surname><given-names>P.</given-names></name><name><surname>Pallasch</surname><given-names>E.</given-names></name><name><surname>Kerber</surname><given-names>R.</given-names></name><name><surname>Rieger</surname><given-names>T.</given-names></name><name><surname>Wurr</surname><given-names>S.</given-names></name><name><surname>Bockholt</surname><given-names>S.</given-names></name><name><surname>P&#x000e9;rez-Gir&#x000f3;n</surname><given-names>J.V.</given-names></name><name><surname>Krasemann</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Chimeric Mice with Competent Hematopoietic Immunity Reproduce Key Features of Severe Lassa Fever</article-title><source>PLoS Pathog.</source><year>2016</year><volume>12</volume><elocation-id>e1005656</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005656</pub-id><pub-id pub-id-type="pmid">27191716</pub-id></element-citation></ref><ref id="B80-vaccines-08-00098"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akinci</surname><given-names>E.</given-names></name><name><surname>Yilmaz</surname><given-names>M.</given-names></name><name><surname>Bodur</surname><given-names>H.</given-names></name><name><surname>Ong&#x000fc;r&#x000fc;</surname><given-names>P.</given-names></name><name><surname>Bayazit</surname><given-names>F.N.</given-names></name><name><surname>Erbay</surname><given-names>A.</given-names></name><name><surname>Ozet</surname><given-names>G.</given-names></name></person-group><article-title>Analysis of lymphocyte subgroups in Crimean-Congo hemorrhagic fever</article-title><source>Int. J. Infect. Dis.</source><year>2009</year><volume>13</volume><fpage>560</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2008.08.027</pub-id><pub-id pub-id-type="pmid">19112036</pub-id></element-citation></ref><ref id="B81-vaccines-08-00098"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>W.C.</given-names></name><name><surname>Khan</surname><given-names>A.M.</given-names></name></person-group><article-title>Mapping HLA-A2, -A3 and -B7 supertype-restricted T-cell epitopes in the ebolavirus proteome</article-title><source>BMC Genom.</source><year>2018</year><volume>19</volume><elocation-id>42</elocation-id><pub-id pub-id-type="doi">10.1186/s12864-017-4328-8</pub-id></element-citation></ref><ref id="B82-vaccines-08-00098"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenney</surname><given-names>L.L.</given-names></name><name><surname>Shultz</surname><given-names>L.D.</given-names></name><name><surname>Greiner</surname><given-names>D.L.</given-names></name><name><surname>Brehm</surname><given-names>M.A.</given-names></name></person-group><article-title>Humanized Mouse Models for Transplant Immunology</article-title><source>Am. J. Transpl.</source><year>2016</year><volume>16</volume><fpage>389</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1111/ajt.13520</pub-id></element-citation></ref><ref id="B83-vaccines-08-00098"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marzi</surname><given-names>A.</given-names></name><name><surname>Engelmann</surname><given-names>F.</given-names></name><name><surname>Feldmann</surname><given-names>F.</given-names></name><name><surname>Haberthur</surname><given-names>K.</given-names></name><name><surname>Shupert</surname><given-names>W.L.</given-names></name><name><surname>Brining</surname><given-names>D.</given-names></name><name><surname>Scott</surname><given-names>D.P.</given-names></name><name><surname>Geisbert</surname><given-names>T.W.</given-names></name><name><surname>Kawaoka</surname><given-names>Y.</given-names></name><name><surname>Katze</surname><given-names>M.G.</given-names></name><etal/></person-group><article-title>Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>1893</fpage><lpage>1898</lpage><pub-id pub-id-type="doi">10.1073/pnas.1209591110</pub-id><?supplied-pmid 23319647?><pub-id pub-id-type="pmid">23319647</pub-id></element-citation></ref><ref id="B84-vaccines-08-00098"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kupferschmidt</surname><given-names>K.</given-names></name></person-group><article-title>Successful Ebola treatments promise to tame outbreak</article-title><source>Science</source><year>2019</year><volume>365</volume><fpage>628</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.1126/science.365.6454.628</pub-id><?supplied-pmid 31416941?><pub-id pub-id-type="pmid">31416941</pub-id></element-citation></ref><ref id="B85-vaccines-08-00098"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagstaffe</surname><given-names>H.R.</given-names></name><name><surname>Clutterbuck</surname><given-names>E.A.</given-names></name><name><surname>Bockstal</surname><given-names>V.</given-names></name><name><surname>Stoop</surname><given-names>J.N.</given-names></name><name><surname>Luhn</surname><given-names>K.</given-names></name><name><surname>Douoguih</surname><given-names>M.</given-names></name><name><surname>Shukarev</surname><given-names>G.</given-names></name><name><surname>Snape</surname><given-names>M.D.</given-names></name><name><surname>Pollard</surname><given-names>A.J.</given-names></name><name><surname>Riley</surname><given-names>E.M.</given-names></name><etal/></person-group><article-title>Antibody-Dependent Natural Killer Cell Activation after Ebola Vaccination</article-title><source>J. Infect. Dis.</source><year>2019</year><pub-id pub-id-type="doi">10.1093/infdis/jiz657</pub-id><?supplied-pmid 31821493?><pub-id pub-id-type="pmid">31821493</pub-id></element-citation></ref><ref id="B86-vaccines-08-00098"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baxter</surname><given-names>A.G.</given-names></name><name><surname>Cooke</surname><given-names>A.</given-names></name></person-group><article-title>Complement Lytic Activity Has No Role in the Pathogenesis of Autoimmune Diabetes in NOD Mice</article-title><source>Diabetes</source><year>1993</year><volume>42</volume><fpage>1574</fpage><lpage>1578</lpage><pub-id pub-id-type="doi">10.2337/diab.42.11.1574</pub-id><?supplied-pmid 8405697?><pub-id pub-id-type="pmid">8405697</pub-id></element-citation></ref><ref id="B87-vaccines-08-00098"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Gaetano</surname><given-names>N.</given-names></name><name><surname>Cittera</surname><given-names>E.</given-names></name><name><surname>Nota</surname><given-names>R.</given-names></name><name><surname>Vecchi</surname><given-names>A.</given-names></name><name><surname>Grieco</surname><given-names>V.</given-names></name><name><surname>Scanziani</surname><given-names>E.</given-names></name><name><surname>Botto</surname><given-names>M.</given-names></name><name><surname>Introna</surname><given-names>M.</given-names></name><name><surname>Golay</surname><given-names>J.</given-names></name></person-group><article-title>Complement activation determines the therapeutic activity of rituximab in vivo</article-title><source>J. Immunol.</source><year>2003</year><volume>171</volume><fpage>1581</fpage><lpage>1587</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.171.3.1581</pub-id><pub-id pub-id-type="pmid">12874252</pub-id></element-citation></ref><ref id="B88-vaccines-08-00098"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teijaro</surname><given-names>J.R.</given-names></name><name><surname>Walsh</surname><given-names>K.B.</given-names></name><name><surname>Cahalan</surname><given-names>S.</given-names></name><name><surname>Fremgen</surname><given-names>D.M.</given-names></name><name><surname>Roberts</surname><given-names>E.</given-names></name><name><surname>Scott</surname><given-names>F.</given-names></name><name><surname>Martinborough</surname><given-names>E.</given-names></name><name><surname>Peach</surname><given-names>R.</given-names></name><name><surname>Oldstone</surname><given-names>M.B.</given-names></name><name><surname>Rosen</surname><given-names>H.</given-names></name></person-group><article-title>Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection</article-title><source>Cell</source><year>2011</year><volume>146</volume><fpage>980</fpage><lpage>991</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.08.015</pub-id><?supplied-pmid 21925319?><pub-id pub-id-type="pmid">21925319</pub-id></element-citation></ref><ref id="B89-vaccines-08-00098"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheerlinck</surname><given-names>J.-P.Y.</given-names></name></person-group><article-title>Functional and structural comparison of cytokines in different species</article-title><source>Vet. Immunol. Immunopathol.</source><year>1999</year><volume>72</volume><fpage>39</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/S0165-2427(99)00115-4</pub-id><pub-id pub-id-type="pmid">10614491</pub-id></element-citation></ref><ref id="B90-vaccines-08-00098"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maes</surname><given-names>P.</given-names></name><name><surname>Alkhovsky</surname><given-names>S.V.</given-names></name><name><surname>Bao</surname><given-names>Y.</given-names></name><name><surname>Beer</surname><given-names>M.</given-names></name><name><surname>Birkhead</surname><given-names>M.</given-names></name><name><surname>Briese</surname><given-names>T.</given-names></name><name><surname>Buchmeier</surname><given-names>M.J.</given-names></name><name><surname>Calisher</surname><given-names>C.H.</given-names></name><name><surname>Charrel</surname><given-names>R.N.</given-names></name><name><surname>Choi</surname><given-names>I.R.</given-names></name><etal/></person-group><article-title>Taxonomy of the family Arenaviridae and the order Bunyavirales: Update 2018</article-title><source>Arch. Virol.</source><year>2018</year><volume>163</volume><fpage>2295</fpage><lpage>2310</lpage><pub-id pub-id-type="doi">10.1007/s00705-018-3843-5</pub-id><pub-id pub-id-type="pmid">29680923</pub-id></element-citation></ref><ref id="B91-vaccines-08-00098"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Branco</surname><given-names>L.M.</given-names></name><name><surname>Boisen</surname><given-names>M.L.</given-names></name><name><surname>Andersen</surname><given-names>K.G.</given-names></name><name><surname>Grove</surname><given-names>J.N.</given-names></name><name><surname>Moses</surname><given-names>L.M.</given-names></name><name><surname>Muncy</surname><given-names>I.J.</given-names></name><name><surname>Henderson</surname><given-names>L.A.</given-names></name><name><surname>Schieffellin</surname><given-names>J.S.</given-names></name><name><surname>Robinson</surname><given-names>J.E.</given-names></name><name><surname>Bangura</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Lassa hemorrhagic fever in a late term pregnancy from northern Sierra Leone with a positive maternal outcome: Case report</article-title><source>Virol. J.</source><year>2011</year><volume>8</volume><fpage>404</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-8-404</pub-id><pub-id pub-id-type="pmid">21843352</pub-id></element-citation></ref><ref id="B92-vaccines-08-00098"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McElroy</surname><given-names>A.K.</given-names></name><name><surname>Akondy</surname><given-names>R.S.</given-names></name><name><surname>Harmon</surname><given-names>J.R.</given-names></name><name><surname>Ellebedy</surname><given-names>A.H.</given-names></name><name><surname>Cannon</surname><given-names>D.</given-names></name><name><surname>Klena</surname><given-names>J.D.</given-names></name><name><surname>Sidney</surname><given-names>J.</given-names></name><name><surname>Sette</surname><given-names>A.</given-names></name><name><surname>Mehta</surname><given-names>A.K.</given-names></name><name><surname>Kraft</surname><given-names>C.S.</given-names></name><etal/></person-group><article-title>A Case of Human Lassa Virus Infection with Robust Acute T-Cell Activation and Long-Term Virus-Specific T-Cell Responses</article-title><source>J. Infect. Dis.</source><year>2017</year><volume>215</volume><fpage>1862</fpage><lpage>1872</lpage><pub-id pub-id-type="doi">10.1093/infdis/jix201</pub-id><pub-id pub-id-type="pmid">28863472</pub-id></element-citation></ref><ref id="B93-vaccines-08-00098"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitz</surname><given-names>H.</given-names></name><name><surname>K&#x000f6;hler</surname><given-names>B.</given-names></name><name><surname>Laue</surname><given-names>T.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name><name><surname>Veldkamp</surname><given-names>P.J.</given-names></name><name><surname>G&#x000fc;nther</surname><given-names>S.</given-names></name><name><surname>Emmerich</surname><given-names>P.</given-names></name><name><surname>Geisen</surname><given-names>H.P.</given-names></name><name><surname>Fleischer</surname><given-names>K.</given-names></name><name><surname>Beersma</surname><given-names>M.F.C.</given-names></name><etal/></person-group><article-title>Monitoring of clinical and laboratory data in two cases of imported Lassa fever</article-title><source>Microbes Infect.</source><year>2002</year><volume>4</volume><fpage>43</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/S1286-4579(01)01508-8</pub-id><pub-id pub-id-type="pmid">11825774</pub-id></element-citation></ref><ref id="B94-vaccines-08-00098"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Branco</surname><given-names>L.M.</given-names></name><name><surname>Grove</surname><given-names>J.N.</given-names></name><name><surname>Boisen</surname><given-names>M.L.</given-names></name><name><surname>Shaffer</surname><given-names>J.G.</given-names></name><name><surname>Goba</surname><given-names>A.</given-names></name><name><surname>Fullah</surname><given-names>M.</given-names></name><name><surname>Momoh</surname><given-names>M.</given-names></name><name><surname>Grant</surname><given-names>D.S.</given-names></name><name><surname>Garry</surname><given-names>R.F.</given-names></name></person-group><article-title>Emerging trends in Lassa fever: Redefining the role of immunoglobulin M and inflammation in diagnosing acute infection</article-title><source>Virol. J.</source><year>2011</year><volume>8</volume><fpage>478</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-8-478</pub-id><?supplied-pmid 22023795?><pub-id pub-id-type="pmid">22023795</pub-id></element-citation></ref><ref id="B95-vaccines-08-00098"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kastello</surname><given-names>M.D.</given-names></name><name><surname>Eddy</surname><given-names>G.A.</given-names></name><name><surname>Kuehne</surname><given-names>R.W.</given-names></name></person-group><article-title>A rhesus monkey model for the study of Bolivian hemorrhagic fever</article-title><source>J. Infect. Dis.</source><year>1976</year><volume>133</volume><fpage>57</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1093/infdis/133.1.57</pub-id><?supplied-pmid 173762?><pub-id pub-id-type="pmid">173762</pub-id></element-citation></ref><ref id="B96-vaccines-08-00098"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lange</surname><given-names>J.V.</given-names></name><name><surname>Mitchell</surname><given-names>S.W.</given-names></name><name><surname>McCormick</surname><given-names>J.B.</given-names></name><name><surname>Walker</surname><given-names>D.H.</given-names></name><name><surname>Evatt</surname><given-names>B.L.</given-names></name><name><surname>Ramsey</surname><given-names>R.R.</given-names></name></person-group><article-title>Kinetic study of platelets and fibrinogen in Lassa virus-infected monkeys and early pathologic events in Mopeia virus-infected monkeys</article-title><source>Am. J. Trop. Med. Hyg.</source><year>1985</year><volume>34</volume><fpage>999</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.1985.34.999</pub-id><?supplied-pmid 4037187?><pub-id pub-id-type="pmid">4037187</pub-id></element-citation></ref><ref id="B97-vaccines-08-00098"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lukashevich</surname><given-names>I.S.</given-names></name><name><surname>Carrion</surname><given-names>R.</given-names></name><name><surname>Salvato</surname><given-names>M.S.</given-names></name><name><surname>Mansfield</surname><given-names>K.</given-names></name><name><surname>Brasky</surname><given-names>K.</given-names></name><name><surname>Zapata</surname><given-names>J.</given-names></name><name><surname>Cairo</surname><given-names>C.</given-names></name><name><surname>Goicochea</surname><given-names>M.</given-names></name><name><surname>Hoosien</surname><given-names>G.E.</given-names></name><name><surname>Ticer</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>5246</fpage><lpage>5254</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.07.057</pub-id><?supplied-pmid 18692539?><pub-id pub-id-type="pmid">18692539</pub-id></element-citation></ref><ref id="B98-vaccines-08-00098"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baize</surname><given-names>S.</given-names></name><name><surname>Marianneau</surname><given-names>P.</given-names></name><name><surname>Loth</surname><given-names>P.</given-names></name><name><surname>Reynard</surname><given-names>S.</given-names></name><name><surname>Journeaux</surname><given-names>A.</given-names></name><name><surname>Chevallier</surname><given-names>M.</given-names></name><name><surname>Tordo</surname><given-names>N.</given-names></name><name><surname>Deubel</surname><given-names>V.</given-names></name><name><surname>Contamin</surname><given-names>H.</given-names></name></person-group><article-title>Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys</article-title><source>J. Virol.</source><year>2009</year><volume>83</volume><fpage>5890</fpage><lpage>5903</lpage><pub-id pub-id-type="doi">10.1128/JVI.01948-08</pub-id><pub-id pub-id-type="pmid">19297492</pub-id></element-citation></ref><ref id="B99-vaccines-08-00098"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenyon</surname><given-names>R.H.</given-names></name><name><surname>Green</surname><given-names>D.E.</given-names></name><name><surname>Eddy</surname><given-names>G.A.</given-names></name><name><surname>Peters</surname><given-names>C.J.</given-names></name></person-group><article-title>Treatment of Junin VIrus-Infected Guinea Pigs with Immune Serum: Development of Late Neurological Disease</article-title><source>J. Med. Virol.</source><year>1986</year><volume>20</volume><fpage>207</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1002/jmv.1890200303</pub-id><pub-id pub-id-type="pmid">3023540</pub-id></element-citation></ref><ref id="B100-vaccines-08-00098"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>W.C.</given-names></name><name><surname>Geisbert</surname><given-names>T.W.</given-names></name><name><surname>Huggins</surname><given-names>J.W.</given-names></name><name><surname>Jahrling</surname><given-names>P.B.</given-names></name></person-group><article-title>Experimental Infection of Guinea Pigs With Venezuelan Hemorrhagic Fever Virus (Guanarito): A Model of Human Disease</article-title><source>Am. J. Trop. Med. Hyg.</source><year>1996</year><volume>55</volume><fpage>81</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.1996.55.81</pub-id><pub-id pub-id-type="pmid">8702027</pub-id></element-citation></ref><ref id="B101-vaccines-08-00098"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bird</surname><given-names>B.H.</given-names></name><name><surname>Dodd</surname><given-names>K.A.</given-names></name><name><surname>Erickson</surname><given-names>B.R.</given-names></name><name><surname>Albari&#x000f1;o</surname><given-names>C.G.</given-names></name><name><surname>Chakrabarti</surname><given-names>A.K.</given-names></name><name><surname>McMullan</surname><given-names>L.K.</given-names></name><name><surname>Bergeron</surname><given-names>E.</given-names></name><name><surname>Str&#x000f6;eher</surname><given-names>U.</given-names></name><name><surname>Cannon</surname><given-names>D.</given-names></name><name><surname>Martin</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Severe hemorrhagic fever in strain 13/N guinea pigs infected with Lujo virus</article-title><source>PLoS Negl. Trop. Dis.</source><year>2012</year><volume>6</volume><elocation-id>e1801</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0001801</pub-id><pub-id pub-id-type="pmid">22953019</pub-id></element-citation></ref><ref id="B102-vaccines-08-00098"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradfute</surname><given-names>S.B.</given-names></name><name><surname>Stuthman</surname><given-names>K.S.</given-names></name><name><surname>Shurtleff</surname><given-names>A.C.</given-names></name><name><surname>Bavari</surname><given-names>S.</given-names></name></person-group><article-title>A STAT-1 knockout mouse model for Machupo virus pathogenesis</article-title><source>Virol. J.</source><year>2011</year><volume>8</volume><fpage>300</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-8-300</pub-id><pub-id pub-id-type="pmid">21672221</pub-id></element-citation></ref><ref id="B103-vaccines-08-00098"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patterson</surname><given-names>M.</given-names></name><name><surname>Seregin</surname><given-names>A.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Kolokoltsova</surname><given-names>O.</given-names></name><name><surname>Smith</surname><given-names>J.</given-names></name><name><surname>Miller</surname><given-names>M.</given-names></name><name><surname>Smith</surname><given-names>J.</given-names></name><name><surname>Yun</surname><given-names>N.</given-names></name><name><surname>Poussard</surname><given-names>A.</given-names></name><name><surname>Grant</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Rescue of a Recombinant Machupo Virus from Cloned cDNAs and In Vivo Characterization in Interferon (/) Receptor Double Knockout Mice</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>1914</fpage><lpage>1923</lpage><pub-id pub-id-type="doi">10.1128/JVI.02925-13</pub-id><?supplied-pmid 24284323?><pub-id pub-id-type="pmid">24284323</pub-id></element-citation></ref><ref id="B104-vaccines-08-00098"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sevilla</surname><given-names>N.</given-names></name><name><surname>Kunz</surname><given-names>S.</given-names></name><name><surname>Holz</surname><given-names>A.</given-names></name><name><surname>Lewicki</surname><given-names>H.</given-names></name><name><surname>Homann</surname><given-names>D.</given-names></name><name><surname>Yamada</surname><given-names>H.</given-names></name><name><surname>Campbell</surname><given-names>K.P.</given-names></name><name><surname>de La Torre</surname><given-names>J.C.</given-names></name><name><surname>Oldstone</surname><given-names>M.B.</given-names></name></person-group><article-title>Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells</article-title><source>J. Exp. Med.</source><year>2000</year><volume>192</volume><fpage>1249</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1084/jem.192.9.1249</pub-id><?supplied-pmid 11067874?><pub-id pub-id-type="pmid">11067874</pub-id></element-citation></ref><ref id="B105-vaccines-08-00098"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baize</surname><given-names>S.</given-names></name><name><surname>Kaplon</surname><given-names>J.</given-names></name><name><surname>Faure</surname><given-names>C.</given-names></name><name><surname>Pannetier</surname><given-names>D.</given-names></name><name><surname>Georges-Courbot</surname><given-names>M.-C.</given-names></name><name><surname>Deubel</surname><given-names>V.</given-names></name></person-group><article-title>Lassa Virus Infection of Human Dendritic Cells and Macrophages Is Productive but Fails to Activate Cells</article-title><source>J. Immunol.</source><year>2004</year><volume>172</volume><fpage>2861</fpage><lpage>2869</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.5.2861</pub-id><?supplied-pmid 14978087?><pub-id pub-id-type="pmid">14978087</pub-id></element-citation></ref><ref id="B106-vaccines-08-00098"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akkina</surname><given-names>R.</given-names></name><name><surname>Allam</surname><given-names>A.</given-names></name><name><surname>Balazs</surname><given-names>A.B.</given-names></name><name><surname>Blankson</surname><given-names>J.N.</given-names></name><name><surname>Burnett</surname><given-names>J.C.</given-names></name><name><surname>Casares</surname><given-names>S.</given-names></name><name><surname>Garcia</surname><given-names>J.V.</given-names></name><name><surname>Hasenkrug</surname><given-names>K.J.</given-names></name><name><surname>Kashanchi</surname><given-names>F.</given-names></name><name><surname>Kitchen</surname><given-names>S.G.</given-names></name><etal/></person-group><article-title>Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID &#x0201c;Meet the Experts&#x0201d; 2015 Workshop Summary</article-title><source>AIDS Res. Hum. Retrovir.</source><year>2016</year><volume>32</volume><fpage>109</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1089/aid.2015.0258</pub-id><?supplied-pmid 26670361?><pub-id pub-id-type="pmid">26670361</pub-id></element-citation></ref><ref id="B107-vaccines-08-00098"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majji</surname><given-names>S.</given-names></name><name><surname>Wijayalath</surname><given-names>W.</given-names></name><name><surname>Shashikumar</surname><given-names>S.</given-names></name><name><surname>Pow-Sang</surname><given-names>L.</given-names></name><name><surname>Villasante</surname><given-names>E.</given-names></name><name><surname>Brumeanu</surname><given-names>T.D.</given-names></name><name><surname>Casares</surname><given-names>S.</given-names></name></person-group><article-title>Differential effect of HLA class-I versus class-II transgenes on human T and B cell reconstitution and function in NRG mice</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>28093</fpage><pub-id pub-id-type="doi">10.1038/srep28093</pub-id><?supplied-pmid 27323875?><pub-id pub-id-type="pmid">27323875</pub-id></element-citation></ref><ref id="B108-vaccines-08-00098"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Borsotti</surname><given-names>C.</given-names></name><name><surname>Schickel</surname><given-names>J.-N.</given-names></name><name><surname>Zhu</surname><given-names>S.</given-names></name><name><surname>Strowig</surname><given-names>T.</given-names></name><name><surname>Eynon</surname><given-names>E.E.</given-names></name><name><surname>Frleta</surname><given-names>D.</given-names></name><name><surname>Gurer</surname><given-names>C.</given-names></name><name><surname>Murphy</surname><given-names>A.J.</given-names></name><name><surname>Yancopoulos</surname><given-names>G.D.</given-names></name><etal/></person-group><article-title>A novel humanized mouse model with significant improvement of class- switched, antigen-specific antibody production</article-title><source>Blood</source><year>2017</year><volume>129</volume><fpage>959</fpage><lpage>969</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-04-709584</pub-id><pub-id pub-id-type="pmid">28077418</pub-id></element-citation></ref><ref id="B109-vaccines-08-00098"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dagur</surname><given-names>R.S.</given-names></name><name><surname>Branch-Woods</surname><given-names>A.</given-names></name><name><surname>Mathews</surname><given-names>S.</given-names></name><name><surname>Joshi</surname><given-names>P.S.</given-names></name><name><surname>Quadros</surname><given-names>R.M.</given-names></name><name><surname>Harms</surname><given-names>D.W.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Miles</surname><given-names>S.M.</given-names></name><name><surname>Pirruccello</surname><given-names>S.J.</given-names></name><name><surname>Gurumurthy</surname><given-names>C.B.</given-names></name><etal/></person-group><article-title>Human-like NSG mouse glycoproteins sialylation pattern changes the phenotype of human lymphocytes and sensitivity to HIV-1 infection</article-title><source>BMC Immunol.</source><year>2019</year><volume>20</volume><elocation-id>2</elocation-id><pub-id pub-id-type="doi">10.1186/s12865-018-0279-3</pub-id><?supplied-pmid 30616506?><pub-id pub-id-type="pmid">30616506</pub-id></element-citation></ref><ref id="B110-vaccines-08-00098"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brehm</surname><given-names>M.A.</given-names></name><name><surname>Kenney</surname><given-names>L.L.</given-names></name><name><surname>Wiles</surname><given-names>M.V.</given-names></name><name><surname>Low</surname><given-names>B.E.</given-names></name><name><surname>Tisch</surname><given-names>R.M.</given-names></name><name><surname>Burzenski</surname><given-names>L.</given-names></name><name><surname>Mueller</surname><given-names>C.</given-names></name><name><surname>Greiner</surname><given-names>D.L.</given-names></name><name><surname>Shultz</surname><given-names>L.D.</given-names></name></person-group><article-title>Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression</article-title><source>FASEB J.</source><year>2019</year><volume>33</volume><fpage>3137</fpage><lpage>3151</lpage><pub-id pub-id-type="doi">10.1096/fj.201800636R</pub-id><pub-id pub-id-type="pmid">30383447</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="vaccines-08-00098-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>HIS models used in research of high-containment VHFs.</p></caption><graphic xlink:href="vaccines-08-00098-g001"/></fig><table-wrap id="vaccines-08-00098-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">vaccines-08-00098-t001_Table 1</object-id><label>Table 1</label><caption><p>Human immune system (HIS) mice used in viral hemorrhagic fever research.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Common Name</th><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Background Strain</th><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Transgenic Human Proteins</th><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Humanization Method</th><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Notes</th><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">NSG-huPBL</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">NOD/SCID <italic>Il2r&#x00263;<sub>c</sub></italic><sup>&#x02212;/&#x02212;</sup></td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">PBL</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Highly functional T cell engraftment; GVHD within &#x02248;4&#x02013;5 weeks</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B11-vaccines-08-00098" ref-type="bibr">11</xref>,<xref rid="B23-vaccines-08-00098" ref-type="bibr">23</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">hu-NSG-A2</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">NOD/SCID <italic>Il2r&#x00263;<sub>c</sub></italic><sup>&#x02212;/&#x02212;</sup></td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">HLA-A2</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">HSC</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">HLA-matched human T cells can recognize infected mouse cells</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B19-vaccines-08-00098" ref-type="bibr">19</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">NSG-BLT</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">NOD/SCID <italic>Il2r&#x00263;<sub>c</sub></italic><sup>&#x02212;/&#x02212;</sup></td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">BLT</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Susceptible to GVHD </td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-vaccines-08-00098" ref-type="bibr">27</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">hu&#x02011;NSG&#x02011;SGM3</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">NOD/SCID <italic>Il2r&#x00263;<sub>c</sub></italic><sup>&#x02212;/&#x02212;</sup></td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">SCF<break/>GM-CSF<break/>IL-3</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">HSC</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Improved human myeloid cell development</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-vaccines-08-00098" ref-type="bibr">30</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">TKO-BLT</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 <italic>Rag2</italic><sup>&#x02212;/&#x02212;</sup><italic>Il2r&#x00263;<sub>c</sub></italic><sup>&#x02212;/&#x02212;</sup><italic>Cd47</italic><sup>&#x02212;/&#x02212;</sup></td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">BLT</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">GVHD resistant</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B15-vaccines-08-00098" ref-type="bibr">15</xref>,<xref rid="B31-vaccines-08-00098" ref-type="bibr">31</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>PBL, peripheral blood lymphocytes; BLT, bone marrow-liver-thymus; GVHD, graft vs. host disease; HSC, hematopoietic stem cells.</p></fn></table-wrap-foot></table-wrap><table-wrap id="vaccines-08-00098-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">vaccines-08-00098-t002_Table 2</object-id><label>Table 2</label><caption><p>Summary of viral hemorrhagic fever (VHF) research in HIS mice.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Agent</th><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mouse Model</th><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus Strain</th><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Route, Dose</th><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Survival</th><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Main Findings</th><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><italic>Filoviridae</italic></bold>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="5" align="left" valign="top" style="border-bottom:solid thin" colspan="1">EBOV</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">NSG-huPBL</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">MA-EBOV<break/>Mayinga</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IP, 10&#x000b3; PFU<break/>IP, 10&#x000b3; PFU</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">0%<break/>100%</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">MA-EBOV infections induced human lymphocyte apoptosis and human cytokine response, but wild-type EBOV (Mayinga) infection did not</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B36-vaccines-08-00098" ref-type="bibr">36</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">hu-NSG-A2</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Mayinga<break/>Mayinga<break/>Makona</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IP, 10&#x000b3; FFU<break/>IN, 10&#x000b3; FFU<break/>IN, 10&#x000b3; FFU</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">13% (1/8)<break/>7% (1/14)<break/>57% (4/7)</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Disease severity may correlate with human cell engraftment efficiency</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-vaccines-08-00098" ref-type="bibr">37</xref>,<xref rid="B38-vaccines-08-00098" ref-type="bibr">38</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">hu&#x02011;NSG&#x02011;SGM3</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Makona</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IM, 10&#x000b3; FFU</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">50% (3/6) <sup>&#x02021;</sup></td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Higher EBOV replication in liver compared to RESTV investigated in parallel</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B39-vaccines-08-00098" ref-type="bibr">39</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">NSG-BLT</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Mayinga<break/><break/>Makona</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IP, 10&#x000b2;, 10&#x000b3; and 10<sup>5</sup> TCID<sub>50</sub><break/>IP, 10&#x000b2; TCID<sub>50</sub></td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">0% (0/13)<break/>25% (1/4)</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Donor-dependent variations in severity observed</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B40-vaccines-08-00098" ref-type="bibr">40</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">TKO-BLT</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Makona</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IM, 10<sup>3</sup> FFU</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">44% (4/9) *</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Accumulation of dysfunctional M2-like macrophages</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B41-vaccines-08-00098" ref-type="bibr">41</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">SUDV</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">hu-NSG-A2</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Gulu-808892</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IN, 10<sup>3</sup> FFU</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">29% (2/7)</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Lethality rate analogous to human case fatality rates</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-vaccines-08-00098" ref-type="bibr">37</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">TAFV</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">hu-NSG-A2</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Pauleoula-CI</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IN, 10<sup>3</sup> FFU</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">82% (9/11)</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Lethal TAFV infection produced high serum AST but low viremia</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-vaccines-08-00098" ref-type="bibr">37</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">BDBV</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">hu-NSG-A2</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Bundibugyo-200706291</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IN, 10<sup>3</sup> FFU</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">29% (2/7)</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Lethality rate similar to human case fatality rates</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-vaccines-08-00098" ref-type="bibr">37</xref>]</td></tr><tr><td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">RESTV</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">hu&#x02011;NSG&#x02011;SGM3</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">RESTV-Pennsylvania</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IM, 10<sup>3</sup> FFU</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">100% (6/6) <sup>&#x02021;</sup></td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">No gross pathology, RESTV levels lower than EBOV levels in liver</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B39-vaccines-08-00098" ref-type="bibr">39</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">hu-NSG-A2</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">RESTV-Pennsylvania</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IN, 10<sup>3</sup> FFU</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">80% (12/15)</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Lethal RESTV infection correlated with inflammation and high RESTV replication in the liver</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-vaccines-08-00098" ref-type="bibr">37</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">MARV</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">TKO-BLT</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Angola-368</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IM, 10<sup>3</sup> FFU</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">25% (2/8) *</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">MARV replicated similarly to EBOV, but induced more functional innate immune response</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B41-vaccines-08-00098" ref-type="bibr">41</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><italic>Nairoviridae</italic></bold>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">CCHFV</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">hu&#x02011;NSG&#x02011;SGM3</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Turkey-200406546<break/>Oman-199809166</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IP, 10<sup>4</sup> TCID<sub>50</sub><break/>IP, 10<sup>4</sup> TCID<sub>50</sub></td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">0% (0/5)<break/>100% (6/6)</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Strain-dependent severity. Time to death 13&#x02013;23 days. Animals with terminal outcomes showed higher levels of perforin positive CD8 T cells. CCHFV-Turkey associated hepatic and neurological histopathology</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B42-vaccines-08-00098" ref-type="bibr">42</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><italic>Phenuiviridae</italic></bold>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">RVFV</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">hu&#x02011;NSG&#x02011;SGM3</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">rZH-501<break/>rZH-501</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IM, 10<sup>1</sup> TCID<sub>50</sub><break/>IM, 10<sup>4</sup> TCID<sub>50</sub></td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">0% (0/7)<break/>0% (0/7)</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Human immune cells did not alter disease course; murine cytokines still influential in humanized mouse models</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B43-vaccines-08-00098" ref-type="bibr">43</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><italic>Hantaviridae</italic></bold>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">HTNV</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">hu-NSG-A2<break/>hu-NSG</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Strain 76-118<break/>Strain 76-118</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IP, 10<sup>5</sup> FFU<break/>IP, 10<sup>5</sup> FFU</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">25% (2/8) *<break/>25% (2/8) *</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Human immune cells increase pathology; human CD8 T cell responses accelerated early pathology; human platelet loss during infection</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B44-vaccines-08-00098" ref-type="bibr">44</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p><sup>&#x02021;</sup>, until 14 dpi; *, until 21 dpi; IM, intramuscular; IN, intranasal; IP, intraperitoneal; MA, mouse-adapted.</p></fn></table-wrap-foot></table-wrap></floats-group></article>